USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS II

Information

  • Patent Application
  • 20230172206
  • Publication Number
    20230172206
  • Date Filed
    April 15, 2021
    3 years ago
  • Date Published
    June 08, 2023
    a year ago
Abstract
The present invention relates to the use of strobilurin type compounds of formula I and the N-oxides and the salts thereof for combating phytopathogenic fungi containing an amino acid substitution F129L in the mitochondrial cytochrome b protein (also referred to as F129L mutation in the mitochondrial cytochrome b gene) conferring resistance to Qo inhibitors, and to methods for combating such fungi. The invention also relates to novel compounds, processes for preparing these compounds, to compositions comprising at least one such compound, and to seeds coated with at least one such compound.
Description
DESCRIPTION

The present invention relates the use of strobilurin type compounds of formula I and the N-oxides and the salts thereof for combating phytopathogenic fungi containing an amino acid substitution F129L in the mitochondrial cytochrome b protein (also referred to as F129L mutation in the mitochondrial cytochrome b gene) conferring resistance to Qo inhibitors (Qol), and to methods for combating such fungi. The invention also relates to novel compounds, processes for preparing these compounds, to compositions comprising at least one such compound, to plant health applications, and to seeds coated with at least one such compound. The present invention also relates to a method for controlling soybean rust fungi (Phakopsora pachyrhizi) with the amino acid substitution F129L in the mitochondrial cytochrome b protein.


“Qo inhibitor,” as used herein, includes any substance that is capable of diminishing and/or inhibiting respiration by binding to a ubihydroquinone oxidation center of a cytochrome bc1 complex in mitochondria. The oxidation center is typically located on the outer side of the inner mitochrondrial membrane. Many of these compounds are also known as strobilurin-type or strobilurin analogue compounds.


The mutation F129L in the mitochondrial cytochrome b (CYTB) gene shall mean any substitution of nucleotides of codon 129 encoding “F” (phenylalanine; e.g. TTT or TTC) that leads to a codon encoding “L” (leucine; e.g. TTA, TTG, TTG, CTT, CTC, CTA or CTG), for example the substitution of the first nucleotide of codon 129 ‘T’ to ‘C’ (TTT to CTT), in the CYTB (cytochrome b) gene resulting in a single amino acid substitution in the position 129 from F to L in the cytochrome b protein. Such F129L mutation is known to confer resistance to Qo inhibitors.


Qol fungicides, often referred to as strobilurin-type fungicides (Sauter 2007: Chapter 13.2. Strobilurins and other complex III inhibitors. In: Kramer, W.; Schirmer, U. (Ed.) - Modern Crop Protection Compounds. Volume 2. Wiley-VCH Verlag 457-495), are conventionally used to control a number of fungal pathogens in crops. Qo inhibitors typically work by inhibiting respiration by binding to a ubihydroquinone oxidation center of a cytochrome bc1 complex (electron transport complex III) in mitochondria. Said oxidation center is located on the outer side of the inner mitochrondrial membrane. A prime example of the use of Qols includes the use of, for example, strobilurins on wheat for the control of Septoria tritici (also known as Mycosphaerella graminicola), which is the cause of wheat leaf blotch. Unfortunately, widespread use of such Qols has resulted in the selection of mutant pathogens which are resistant to such Qols (Gisi et al., Pest Manag Sci 56, 833-841, (2000)). Resistance to Qols has been detected in several phytopathogenic fungi such as Blumeria graminis, Mycosphaerella fijiensis, Pseudoperonspora cubensis or Venturia inaequalis. The major part of resistance to Qols in agricultural uses has been attributed to pathogens containing a single amino acid residue substitution G143A in the cytochrome b gene for their cytochrome bc1 complex, the target protein of Qols which have been found to be controlled by specific Qols (WO 2013/092224). Despite several commercial Qol fungicides have also been widely used in soybean rust control, the single amino acid residue substitution G143A in the cytochrome b protein conferring resistance to Qol fungicides was not observed.


Instead soybean rust acquired a different genetic mutation in the cytochrome b gene causing a single amino acid substitution F129L which also confers resistance against Qol fungicides. The efficacy of Qol fungicides used against soybean rust conventionally, i.e. pyraclostrobin, azoxystrobin, picoxystrobin, orysastrobin, dimoxystrobin and metominostrobin, has decreased to a level with practical problems for agricultural practice (e.g. Klosowski et al (2016) Pest Manag Sci 72, 1211-1215).


Although it seems that trifloxystrobin was less affected by the F129L amino acid substitution to the same degree as other Qol fungicides such as azoxystrobin and pyraclostrobin, trifloxystrobin was never as efficacious on a fungal population bearing the F129L Qol resistance mutation as on a sensitive population (Crop Protection 27, (2008) 427-435).


WO 2017/157923 discloses the use of the tetrazole compound 1-[2-[[1-(4-chlorophenyl)-pyrazol-3-yl]oxymethyl]-3-methylphenyl]-4-methyltetrazol-5-one for combating phytopathogenic fungi containing said F129L amino acid substitution.


Thus, new methods are desirable for controlling pathogen induced diseases in crops comprising plants subjected to pathogens containing a F129L amino acid substitution in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitors. Furthermore, in many cases, in particular at low application rates, the fungicidal activity of the known fungicidal strobilurin compounds is unsatisfactory, especially in case that a high proportion of the fungal pathogens contain a mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors. Besides there is an ongoing need for new fungicidally active compounds which are more effective, less toxic and/or environmentally safer. Based on this, it was also an object of the present invention to provide compounds having improved activity and/or a broader activity spectrum against phytopathogenic fungi and/or even further reduced toxicity against non target organisms such as vertebrates and invertebrates.


The strobilurin-analogue compounds used to combat phytopathogenic fungi containing a F129L amino acid substitution in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitors according to the present invention differ from trifloxystrobin inter alia by containing a specific group attached to the central phenyl ring in ortho position to the side chain defined herein as R3.


Accordingly, the present invention relates to the use of compounds of formula I




embedded image


wherein

  • R1 is selected from O and NH;
  • R2 is selected from CH and N;
  • R3 is selected from halogen, C1-C4-alkyl, C2-C4-alkenyl, C1-C2-monohaloalkyl, C1-C2-dihaloalkyl, monohalo-ethenyl, dihalo-ethenyl, C3-C6-cycloalkyl and —O—C1-C4-alkyl;
  • R4 is selected from C1-C6-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C1-C6-haloalkyl, C2-C4-haloalkenyl, C2-C4-haloalkynyl, —C(═O)—C1-C4-alkyl, -(C1-C2-alkyl)-O-(C1-C2-alkyl), -(C1-C2-alkyl)-O-(C1-C2-haloalkyl) and -C1-C4-alkyl-C3-C6-cycloalkyl;
  • Ra is selected from halogen, CN, —NR5R6, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, —O—C1-C4-alkyl, —C(═N—O—C1-C4-alkyl)-C1-C4-alkyl, —C(═O)—C1-C4-alkyl, —O—CH2—C(═N—O—C1-C4-alkyl)-C1-C4-alkyl, C3-C6-cycloalkyl, C3-C6-cycloalkenyl, -C1-C2-alkyl-C3-C6-cycloalkyl, —O—C3-C6-cycloalkyl, phenyl, 3- to 6-membered heterocycloalkyl, 3- to 6-membered heterocycloalkenyl and 5- or 6-membered heteroaryl,
    • wherein said heterocycloalkyl, heterocycloalkenyl and heteroaryl besides carbon atoms contain 1, 2 or 3 heteroatoms selected from N, O and S,
    • wherein said phenyl, heterocycloalkyl, heterocycloalkenyl and heteroaryl are bound directly or via an oxygen atom or via a C1-C2-alkylene linker,
    • and wherein the aliphatic and cyclic moieties of Ra are unsubstituted or carry 1, 2, 3, 4 or up to the maximum number of identical or different groups Rb
    • Rb is selected from halogen, CN, NH2, NO2, C1-C4-alkyl, C1-C4-haloalkyl, —O—C1-C4-alkyl and —O—C1-C4-haloalkyl;
    • R5, R6 are independently of each other selected from the group consisting of H, C1-C6-alkyl, C1-C6-haloalkyl and C2-C4-alkynyl;
  • n is an integer selected from 0, 1, 2, 3, 4 and 5;
  • and in form or stereoisomers and tautomers thereof, and the N-oxides and the agriculturally acceptable salts thereof, for combating phytopathogenic fungi containing an amino acid substitution F129L in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitors.


The mutation F129L in the cytochrome b (cytb, also referred to as cob) gene shall mean any substitution of nucleotides of codon 129 encoding “F” (phenylalanine; e.g. TTT or TTC) that leads to a codon encoding “L” (leucine; e.g. TTA, TTG, TTG, CTT, CTC, CTA or CTG), for example the substitution of the first nucleotide of codon 129 ‘T’ to ‘C’ (TTT to CTT), in the cytochrome b gene resulting in a single amino acid substitution in the position 129 from F (phenylalanine) to L (leucine) (F129L) in the cytochrome b protein (Cytb). In the present invention, the mutation F129L in the cytochrome b gene shall be understood to be a single amino acid substitution in the position 129 from F (phenylalanine) to L (leucine) (F129L) in the cytochrome b protein.


Many other phytopathogenic fungi acquired the F129L mutation in the cytochrome b gene conferring resistance to Qo inhibitors, such as rusts, in particular soybean rust (Phakopsora pachyrhizi and Phakopsora meibromiae) as well as fungi from the genera Alternaria, Pyrenophora and Rhizoctonia.


Preferred fungal species are Alternaria solani, Phakopsora pachyrhizi, Phakopsora meibromiae, Pyrenophora teres, Pyrenophora tritici-repentis and Rhizoctonia solani; in particular Phakopsora pachyrhizi.


In one aspect, the present invention relates to the method of protecting plants susceptible to and/or under attack by phytopathogenic fungi containing an amino acid substitution F129L in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitors, which method comprises applying to said plants, treating plant propagation material of said plants with, and/or applying to said phytopathogenic fungi, at least one compound of formula I or a composition comprising at least one compound of formula I.


According to another embodiment, the method for combating phytopathogenic fungi, comprises: a) identifying the phytopathogenic fungi containing an amino acid substitution F129L in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitors, or the materials, plants, the soil or seeds that are at risk of being diseased from phytopathogenic fungi as defined herein, and b) treating said fungi or the materials, plants, the soil or plant propagation material with an effective amount of at least one compound of formula I, or a composition comprising it thereof.


The term “phytopathogenic fungi an amino acid substitution F129L in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitors” is to be understood that at least 10% of the fungal isolates to be controlled contain a such F129L substitution in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitors, preferably at least 30%, more preferably at least 50%, even more preferably at at least 75% of the fungi, most preferably between 90 and 100%; in particular between 95 and 100%.


Although the present invention will be described with respect to particular embodiments, this description is not to be construed in a limiting sense.


Before describing in detail exemplary embodiments of the present invention, definitions important for understanding the present invention are given. As used in this specification and in the appended claims, the singular forms of “a” and “an” also include the respective plurals unless the context clearly dictates otherwise. In the context of the present invention, the terms “about” and “approximately” denote an interval of accuracy that a person skilled in the art will understand to still ensure the technical effect of the feature in question. The term typically indicates a deviation from the indicated numerical value of ±20 %, preferably ±15 %, more preferably ±10 %, and even more preferably ±5 %. It is to be understood that the term “comprising” is not limiting. For the purposes of the present invention the term “consisting of” is considered to be a preferred embodiment of the term “comprising of′.


Unless otherwise indicated, the following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention herein and the appended claims. These definitions should not be interpreted in the literal sense as they are not intended to be general definitions and are relevant only for this application.


The term “compounds I” refers to compounds of formula I. Likewise, this terminology applies to all sub-formulae, e. g. “compounds I.2” refers to compounds of formula I.2 or “compounds V” refers to compounds of formula V, etc..


The term “independently” when used in the context of selection of substituents for a variable, it means that where more than one substituent is selected from a number of possible substituents, those substituents may be the same or different.


The organic moieties or groups mentioned in the above definitions of the variables are collective terms for individual listings of the individual group members. The term “Cv-Cw” indicates the number of carbon atom possible in each case.


The term “halogen” refers to fluorine, chlorine, bromine and iodine.


The term “C1-C4-alkyl” refers to a straight-chained or branched saturated hydrocarbon group having 1 to 4 carbon atoms, for example, methyl (CH3), ethyl (C2H5), propyl, 1-methylethyl (isopropyl), butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl.


The term “C2-C4-alkenyl” refers to a straight-chain or branched unsaturated hydrocarbon radical having 2 to 4 carbon atoms and a double bond in any position such as ethenyl, 1-propenyl, 2-propenyl, 1-methylethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl.


The term “C2-C4-alkynyl” refers to a straight-chain or branched unsaturated hydrocarbon radical having 2 to 4 carbon atoms and containing at least one triple bond such as ethynyl, prop-1-ynyl, prop-2-ynyl, but-1-ynyl, but-2-ynyl, but-3-ynyl, 1-methyl-prop-2-ynyl.


The term “C1-C4-haloalkyl” refers to a straight-chained or branched alkyl group having 1 to 4 carbon atoms wherein some or all of the hydrogen atoms in these groups may be replaced by halogen atoms as mentioned above, for example chloromethyl, bromomethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 1-chloroethyl, 1-bromoethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloro-2-fluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl and pentafluoroethyl, 2-fluoropropyl, 3-fluoropropyl, 2,2-difluoropropyl, 2,3-difluoropropyl, 2-chloropropyl, 3-chloropropyl, 2,3-dichloropropyl, 2-bromopropyl, 3-bromopropyl, 3,3,3-trifluoropropyl, 3,3,3-trichloropropyl, CH2—C2F5, CF2—C2F5, CF(CF3)2, 1-(fluoromethyl)-2-fluoroethyl, 1-(chloromethyl)-2-chloroethyl, 1-(bromomethyl)-2-bromoethyl, 4-fluorobutyl, 4-chlorobutyl, 4-bromobutyl or nonafluorobutyl.


The term “monohalo-ethenyl” refers to an ethenyl wherein one hydrogen atom is replaced by a halogen atom, e.g. 1-chloroethenyl, 1-bromoethenyl, 1-fluoroethenyl, 2-fluoroethenyl. Likewise, dihalo-ethenyl” refers to an ethenyl wherein two hydrogen atoms are replaced by halogen atoms.


The term “—O—C1-C4-alkyl” refers to a straight-chain or branched alkyl group having 1 to 4 carbon atoms which is bonded via an oxygen, at any position in the alkyl group, e.g. OCH3, OCH2CH3, O(CH2)2CH3, 1-methylethoxy, O(CH2)3CH3, 1-methyl¬propoxy, 2-methylpropoxy or 1,1-dimethylethoxy.


The term “C3-C6-cycloalkyl” refers to monocyclic saturated hydrocarbon radicals having 3 to 6 carbon ring members, such as cyclopropyl (C3H5), cyclobutyl, cyclopentyl or cyclohexyl. The term “C3-C6-cycloalkenyl” refers to monocyclic saturated hydrocarbon radicals having 3 to 6 carbon ring members and one or more double bonds.


The term “3- to 6-membered heterocycloalkyl” refers to 3- to 6-membered monocyclic saturated ring system having besides carbon atoms one or more heteroatoms, such as O, N, S as ring members. The term “C3-C6-membered heterocycloalkenyl” refers to 3- to 6-membered monocyclic ring system having besides carbon atoms one or more heteroatoms, such as O, N and S as ring members, and one or more double bonds.


The term “-C1-C4-alkyl-C3-C6-cycloalkyl” refers to alkyl having 1 to 4 carbon atoms (as defined above), wherein one hydrogen atom of the alkyl radical is replaced by a cycloalkyl radical having 3 to 6 carbon atoms.


The term “phenyl” refers to C6H5.


The term “5- or 6-membered heteroaryl” which contains 1, 2, 3 or 4 heteroatoms from the group consisting of O, N and S, is to be understood as meaning aromatic heterocycles having 5 or 6 ring atoms. Examples include:

  • 5-membered heteroaryl which in addition to carbon atoms, e.g. contain 1, 2 or 3 N atoms and/or one sulfur and/or one oxygen atom: for example 2-thienyl, 3-thienyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-imidazolyl, 4-imidazolyl and 1,3,4-triazol-2-yl;
  • 6-membered heteroaryl which, in addition to carbon atoms, e.g. contain 1, 2, 3 or 4 N atoms as ring members, e.g. 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl and 2-pyrazinyl.


The term “C1-C2-alkylene linker” means a divalent alkyl group such as —CH2— or —CH2—CH2—that is bound at one end to the core structure of formula I and at the other end to the particular substituent.


As used herein, the “compounds”, in particular “compounds I” include all the stereoisomeric and tautomeric forms and mixtures thereof in all ratios, prodrugs, isotopic forms, their agriculturally acceptable salts, N-oxides and S-oxides thereof.


The term “stereoisomer” is a general term used for all isomers of individual compounds that differ only in the orientation of their atoms in space. The term stereoisomer includes mirror image isomers (enantiomers), mixtures of mirror image isomers (racemates, racemic mixtures), geometric (cis/trans or E/Z) isomers, and isomers of compounds with more than one chiral center that are not mirror images of one another (diastereoisomers). The term “tautomer” refers to the coexistence of two (or more) compounds that differ from each other only in the position of one (or more) mobile atoms and in electron distribution, for example, keto-enol tautomers. The term “agriculturally acceptable salts” as used herein, includes salts of the active compounds which are prepared with acids or bases, depending on the particular substituents found on the compounds described herein. “N-oxide” refers to the oxide of the nitrogen atom of a nitrogen-containing heteroaryl or heterocycle. N-oxide can be formed in the presence of an oxidizing agent for example peroxide such as m-chloro-perbenzoic acid or hydrogen peroxide. N-oxide refers to an amine oxide, also known as amine-N-oxide, and is a chemical compound that contains N→O bond.


In respect of the variables, the embodiments of the intermediates correspond to the embodiments of the compounds I.


Preference is given to those compounds I and where applicable also to compounds of all sub-formulae provided herein, e. g. formulae I.1 and I.2, and to the intermediates such as compounds II, III, IV and V, wherein the substituents and variables (such as n, R1, R2, R3, R4, R5, R6, Ra, and Rb) have independently of each other or more preferably in combination (any possible combination of 2 or more substituents as defined herein) the following meanings:


Preference is also given to the uses, methods, mixtures and compositions, wherein the definitions (such as phytopathogenic fungi, treatments, crops, compounds II, further active ingredients, solvents, solid carriers) have independently of each other or more preferably in combination the following meanings and even more preferably in combination (any possible combination of 2 or more definitions as provided herein) with the preferred meanings of compounds I herein:


One embodiment of the invention relates to the abovementioned use and or method of application (herein collectively referred to as “use”) of compounds I, wherein R1 is selected from O and NH; and R2 is selected from CH and N, provided that R2 is N in case R1 is NH. More preferably R1 is NH. In particular, R1 is NH and R2 is N. Another embodiment relates to the use of compounds I, wherein R1 is O and R2 is CH.


According to another embodiment, R3 is selected from halogen, C1-C4-alkyl, C2-C4-alkenyl, C1-C2-monohaloalkyl, C1-C2-dihaloalkyl, monohalo-ethenyl, dihalo-ethenyl, C3-C5-cycloalkyl and -O-C1-C4-alkyl; preferably from halogen, C1-C2-alkyl, C1-C2-monohaloalkyl, C1-C2-dihaloalkyl, C3-C4-cycloalkyl and —O—C1-C2-alkyl; more preferably from C1-C2-alkyl, C1-C2-monohaloalkyl, C1-C2-dihaloalkyl, C3-C4-cycloalkyl and —O—C1-C2-alkyl; even more preferably from halogen, C1-C2-alkyl, C2-C3-alkenyl, CHF2, CFH2, —O—C1-C2-alkyl and cyclopropyl; even more preferably from C1-C2-alkyl, ethenyl, CHF2, CFH2, OCH3 and cyclopropyl; particularly preferred from methyl, ethenyl, CHF2 and CFH2; in particular methyl.


According to one embodiment, R4 is selected from is selected from C1-C6-alkyl, C2-C4-alkenyl, —C(═O)—C1-C2-alkyl, C1-C6-haloalkyl, C2-C4-haloalkenyl, -(C1-C2-alkyl)-O-(C1-C2-alkyl) and -CH2-cyclopropyl; more preferably from C1-C4-alkyl, C2-C4-alkenyl, —C(═O)—C1-C2-alkyl, C1-C4-haloalkyl, C2-C4-haloalkenyl, -(C1-C2-alkyl)-O-(C1-C2-alkyl) and —CH2—cyclopropyl; even more preferably from C1-C4-alkyl and C1-C4-haloalkyl, particularly preferably from methyl and C1-haloalkyl; in particular methyl.


According to a further embodiment, n is 1, 2, 3, 4 or 5; more preferably n is 1, 2 or 3, even more preferably n is 1 or 2; in particular n is 1.


According to a further embodiment, n is 0, 1, 2 or 3, more preferably 0, 1 or 2, in particular 0.


According to a further embodiment, n is 2 and the two substituents Ra are preferably in positions 2,3 (meaning one substituent in position 2, the other in position 3); 2,4; 2,5; 3,4 or 3,5; even more preferably in positions 2,3 or 2,4.


According to a further embodiment, n is 3 and the two substituents Ra are preferably in positions 2, 3 and 4.


According to a further embodiment, Ra is selected from CN, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, —O—C1-C4-alkyl, —C(═O)—C1-C4-alkyl,—C(═N—O—C1-C4-alkyl)-C1-C4-alkyl, —O—CH2—(═N—O—C1-C4-alkyl)-C1-C4-alkyl, —C(═N—O—C1-C4-alkyl)—C(═O—NH—C1-C4-alkyl), C3-C6-cycloalkyl, C3-C6-cycloalkenyl, -C1-C2-alkyl-C3-C6-cycloalkyl, —O—C3-C6-cycloalkyl, phenyl, 3- to 5-membered heterocycloalkyl, 3- to 5-membered heterocycloalkenyl and 5- or 6-membered heteroaryl, wherein said heterocycloalkyl, hetercycloalkenyl and heteroaryl besides carbon atoms contain 1, 2 or 3 heteroatoms selected from N, O and S, wherein said phenyl, heterocycloalkyl, hetercycloalkenyl and heteroaryl are bound directly or via an oxygen atom or via a C1-C2-alkylene linker, and wherein the aliphatic and cyclic moieties of Ra are unsubstituted or carry 1, 2, or 3 of identical or different groups Rb which independently of one another are selected from halogen, CN, NH2, NO2, C1-C2-alkyl and C1-C2-haloalkyl.


More preferably, Ra is selected from CN, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, —O—C1-C4-alkyl, —C(═O)—C1-C2-alkyl,—C(═N—O—C1-C2-alkyl)-C1-C2-alkyl, —O—CH2—C(═N—O—C1-C2-alkyl)-C1-C2-alkyl, —C(═N—O—C1-C2-alkyl)—C(═O—NH—C1-C2-alkyl), C3-C4-cycloalkyl, C3-C4-cycloalkenyl, -C1-C2-alkyl-C3-C4-cycloalkyl, —O—C3-C4-cycloalkyl, phenyl, 3- to 5-membered heterocycloalkyl and 5- or 6-membered heteroaryl, wherein said heterocycloalkyl and heterocycloalkyl and heteroaryl besides carbon atoms contain 1 or 2 heteroatoms selected from N, O and S, wherein said phenyl, heterocycloalkyl and heteroaryl are bound directly or via an oxygen atom or via a methylene linker, and wherein the aliphatic or cyclic moieties of Ra are unsubstituted or carry 1, 2, or 3 of identical or different groups Rb which independently of one another are selected from halogen, CN, C1-C2-alkyl and C1-C2-haloalkyl.


Even more preferably Ra is selected from C1-C3-alkyl, C2-C3-alkenyl, C2-C3-alkynyl, —O—C1-C3-alkyl, —C(═O)—C1-C2-alkyl,—C(═N—O—C1-C2-alkyl)-C1-C2-alkyl, C3-C4-cycloalkyl, -C1-C2-alkyl-C3-C4-cycloalkyl, —O—C3-C4-cycloalkyl, phenyl, 3- to 5-membered heterocycloalkyl and 5- or 6-membered heteroaryl, wherein said heterocycloalkyl and heteroaryl besides carbon atoms contain 1 or 2 heteroatoms selected from N, O and S, wherein said phenyl and heteroaryl are bound directly or via an oxygen atom or via a methylene linker, and wherein the aliphatic and cyclic moieties of Ra are unsubstituted or carry 1, 2 or 3 of identical or different groups Rb which independently of one another are selected from halogen, CN, methyl and C1-haloalkyl.


Particularly preferred Ra are selected from halogen, C1-C4-alkyl, C2-C3-alkenyl, C2-C3-alkynyl, —O—C1-C4-alkyl, —C(═N—O—C1-C2-alkyl)-C1-C2-alkyl and phenyl, wherein the aliphatic or cyclic moieties of Ra are unsubstituted or carry 1, 2 or 3 of identical or different groups Rb which independently of one another are selected from halogen, CN, methyl and C1-haloalkyl.


According to a further embodiment, R5, R6 are independently of each other preferably selected from the group consisting of H, C1-C4-alkyl, C1-C4-haloalkyl and C2-C4-alkynyl, more preferably from H and C1-C4-alkyl.


According to a further preferred embodiment, the present invention relates to the use of compounds of formula I wherein:

  • R1 is selected from O and NH; and
  • R2 is selected from CH and N, provided that R2 is N in case R1 is NH;
  • R3 is selected from halogen, C1-C4-alkyl, C2-C4-alkenyl, C1-C2-monohaloalkyl, C1-C2-dihaloalkyl, C3-C4-cycloalkyl and —O—C1-C4-alkyl;
  • R4 is selected from C1-C4-alkyl, C1-C4-haloalkyl, —C(═O)—C1-C4-alkyl, -(C1-C2-alkyl)-O-(C1-C2-alkyl) and —CH2—cyclopropyl;
  • Ra is selected from halogen, CN, —NR5R6, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, —O—C1-C4-alkyl, —C(═N—O—C1-C4-alkyl)-C1-C4-alkyl, —C(═0)-C1-C4-alkyl, -0—CH2—C(═N—0-C1-C4-alkyl)-C1-C4-alkyl, C3-C6-cycloalkyl, C3-C6-cycloalkenyl, -C1-C2-alkyl-C3-C6-cycloalkyl, —O—C3-C6-cycloalkyl, phenyl, 3- to 6-membered heterocycloalkyl, 3- to 6-membered heterocycloalkenyl and 5- or 6-membered heteroaryl,
    • wherein said heterocycloalkyl, heterocycloalkenyl and heteroaryl besides carbon atoms contain 1, 2 or 3 heteroatoms selected from N, O and S,
    • wherein said phenyl, heterocycloalkyl, heterocycloalkenyl and heteroaryl are bound directly or via an oxygen atom or via a C1-C2-alkylene linker,
    • and wherein the aliphatic and cyclic moieties of Ra are unsubstituted or carry 1, 2, 3, 4 or up to the maximum number of identical or different groups Rb
    • Rb is selected from halogen, CN, NH2, NO2, C1-C4-alkyl, C1-C4-haloalkyl, —O—C1-C4-alkyl and —O—C1-C4-haloalkyl;
    • R5, R6 are independently of each other selected from the group consisting of H, C1-C6-alkyl and C2-C4-alkynyl;
  • n is an integer selected from 0, 1, 2 and 3;
  • and in form or stereoisomers and tautomers thereof, and the N-oxides and the agriculturally acceptable salts thereof, for combating phytopathogenic fungi containing an amino acid substitution F129L in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitors.


Certain strobilurin type compounds of formula I have been described in EP 370629 and WO 1998/23156. However, it is not mentioned that these compounds inhibit fungal pathogens containing a F129L substitution in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitors.


The compounds according to the present invention differ from those described in the abovementioned publications that R3 is an aliphatic or cyclic substituent and Ra is a specific substituent as defined herein.


Therefore, according to a second aspect, the invention provides novel compounds of formula I which are represented by formula I




embedded image


wherein

  • R1 is selected from O and NH;
  • R2 is selected from CH and N;
  • R3 is selected from C1-C4-alkyl, C2-C4-alkenyl, C1-C2-monohaloalkyl, C1-C2-dihaloalkyl, monohalo-ethenyl, dihalo-ethenyl, C3-C6-cycloalkyl and —O—C1-C4-alkyl;
  • R4 is selected from C1-C6-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C1-C6-haloalkyl, C2-C4-haloalkenyl, C2-C4-haloalkynyl, —C(═O)—C1-C4-alkyl, -(C1-C2-alkyl)-O-(C1-C2-alkyl), -(C1-C2-alkyl)-O-(C1-C2-haloalkyl) and -C1-C4-alkyl-C3-C6-cycloalkyl;
  • Ra is selected from halogen, C1-C4-haloalkyl, C2-C4-haloalkenyl, C2-C4-haloalkynyl, C3-C6-cycloalkyl, C3-C6-cycloalkenyl, -C1-C2-alkyl-C3-C6-cycloalkyl, phenyl, 3- to 6-membered heterocycloalkyl, 3- to 6-membered heterocycloalkenyl and 5- or 6-membered heteroaryl, wherein said heterocycloalkyl, heterocycloalkenyl and heteroaryl besides carbon atoms contain 1, 2 or 3 heteroatoms selected from N, O and S,
    • wherein said phenyl, heterocycloalkyl, heterocycloalkenyl and heteroaryl are bound directly or via an oxygen atom or via a C1-C2-alkylene linker,
    • and wherein the cyclic moieties of Ra carry 1, 2 or 3 substituents selected from halogen and C1-C4-haloalkyl,
    • and wherein the aliphatic and cyclic moieties of Ra further carry 0, 1, 2 or up to the maximum number of identical or different groups Rb:
    • Rb is selected from CN, NH2, NO2, C1-C4-alkyl and —O—C1-C4-alkyl;
  • n is an integer selected from 0, 1, 2, 3, 4 and 5;
  • and in form or stereoisomers and tautomers thereof, and the N-oxides and the agriculturally acceptable salts thereof.


One embodiment of the invention relates to preferred compounds I, wherein R1 is selected from O and NH; and R2 is selected from CH and N, provided that R2 is N in case R1 is NH. More preferably R1 is NH. In particular, R1 is NH and R2 is N. Another embodiment relates to compounds I, wherein R1 is O and R2 is CH.


According to another embodiment, R3 is selected from halogen, C1-C4-alkyl, C2-C3-alkenyl, C1-C2-monohaloalkyl, C1-C2-dihaloalkyl, monohalo-ethenyl, dihalo-ethenyl, C3-C6-cycloalkyl and -O-C1-C4-alkyl; preferably from halogen, C1-C2-alkyl, C1-C2-monohaloalkyl, C1-C2-dihaloalkyl, C3-C4-cycloalkyl and —O—C1-C2-alkyl; preferably selected from C1-C4-alkyl, C2-C3-alkenyl, monohalo-methyl, dihalo-methyl, C3-C4-cycloalkyl and —O—C1-C4-alkyl; further more preferably selected from C1-C2-alkyl, CHF2, CFH2, cyclopropyl and OCH3; particularly preferred from methyl, CHF2 and CFH2; in particular R3 is methyl.


According to a further embodiment, R4 is selected from is selected from C1-C4-alkyl, C2-C4-alkenyl, —C(═O)—C1-C2-alkyl, C1-C4-haloalkyl, C2-C4-haloalkenyl, -(C1-C2-alkyl)-O-(C1-C2-alkyl) and —CH2—cyclopropyl; more preferably from C1-C4-alkyl, and C1-C4-haloalkyl, even more preferably from methyl and C1-haloalkyl; in particular methyl.


According to a further embodiment, n is 1, 2, 3, 4 or 5; more preferably n is 1, 2 or 3, even more preferably n is 1 or 2; in particular n is 1.


According to a further embodiment, n is 0, 1, 2 or 3, more preferably 0, 1 or 2, in particular 0.


According to a further embodiment, n is 2 and the two substituents Ra are preferably in positions 2,3 (meaning one substituent in position 2, the other in position 3); 2,4; 2,5; 3,4 or 3,5; even more preferably in positions 2,3 or 2,4.


According to a further embodiment, n is 3 and the three substituents Ra are preferably in positions 2, 3 and 4.


According to a further embodiment, Ra is selected from halogen, C1-C4-haloalkyl, C2-C4-haloalkenyl, C2-C4-haloalkynyl, C3-C4-cycloalkyl, -C1-C2-alkyl-C3-C4-cycloalkyl, phenyl, 3- to 5-membered heterocycloalkyl and 5- or 6-membered heteroaryl, wherein said heterocycoalkyl and heteroaryl besides carbon atoms contain 1, 2 or 3 heteroatoms selected from N, O and S, wherein said phenyl, heterocycloalkyl and heteroaryl are bound directly or via a C1-C2-alkylene linker, and wherein the cyclic moieties of Ra carry 1, 2 or 3 substituents selected from halogen and C1-C4-haloalkyl.


Preferably, Ra is selected from halogen, C1-C4-haloalkyl, C2-C4-haloalkenyl, C2-C4-haloalkynyl, C3-C4-cycloalkyl, —CH2—C3-C4-cycloalkyl, phenyl, 3- to 4-membered heterocycloalkyl and 5- or 6-membered heteroaryl, wherein said heterocycloalkyl and heteroaryl besides carbon atoms contain 1 or 2 heteroatoms selected from N, O and S, wherein said phenyl, heterocycloalkyl and heteroaryl are bound directly or via a C1-C2-alkylene linker, and wherein the cyclic moieties of Ra carry 1, 2 or 3 substituents selected from halogen and C1-C2-haloalkyl.


More preferably, Ra is selected from halogen, C1-C2-haloalkyl, C2-C4-haloalkenyl, phenyl and 5-membered heteroaryl, wherein said heteroaryl besides carbon atoms contain 1 or 2 heteroatoms selected from N, O and S, wherein said phenyl and heteroaryl are bound directly or via a C1-C2-alkylene linker, and wherein the cyclic moieties of Ra carry 1, 2 or 3 substituents selected from halogen and C1-C2-haloalkyl.


Even more preferably, Ra is selected from F, CI, Br and C1-haloalkyl.


According to the abovementioned embodiments for Ra, the abovementioned heterocycloalkyl is more preferably a 4-membered heterocycloalkyl, wherein said heterocycloalkyl besides carbon atoms contains 1 heteroatom selected from N, O and S, preferably N.


According to the abovementioned embodiments for Ra, the abovementioned heteroaryl is more preferably a 5-membered heteroaryl, wherein said heteroaryl besides carbon atoms contains 1 or 2 heteroatoms selected from N, O and S, preferably from N and O.


According to the abovementioned embodiments for Ra, the aliphatic and cyclic moieties of Ra further carry 0, 1, 2 or up to the maximum number of identical or different groups Rb selected from CN, NH2, NO2, C1-C4-alkyl and —O—C1-C4-alkyl; more preferably only the cyclic moieties of Ra further carry 0, 1, 2 or up to the maximum number of identical or different groups Rb selected from CN, NH2, NO2, C1-C4-alkyl and —O—C1-C4-alkyl; even more preferably only the phenyl moiety of Ra further carries 0, 1 , 2, 3, 4 or 5 identical or different groups Rb selected from CN, C1-C4-alkyl and —O—C1-C4-alkyl; in particular said phenyl further carries 0, 1, 2 or 3 identical or different groups Rb selected from CN, C1-C4-alkyl and -0-C1-C4-alkyl.


According to a further preferred embodiment, the present invention relates to compounds of formula I wherein:

  • R1 is selected from O and NH; and
  • R2 is selected from CH and N, provided that R2 is N in case R1 is NH;
  • R3 is selected from halogen, C1-C4-alkyl, C2-C4-alkenyl, C1-C2-monohaloalkyl, C1-C2-dihaloalkyl, monohalo-ethenyl, dihalo-ethenyl, C3-C4-cycloalkyl and —O—C1-C4-alkyl;
  • R4 is selected from C1-C4-alkyl, C1-C4-haloalkyl, —C(═O)—C1-C4-alkyl, -(C1-C2-alkyl)-O-(C1-C2-alkyl) and —CH2—cyclopropyl;
  • Ra is selected from halogen, C1-C4-haloalkyl, C2-C4-haloalkenyl, phenyl, 3- to 5-membered heterocycloalkyl and 5-membered heteroaryl,
    • wherein said heterocycloalkyl and heteroaryl besides carbon atoms contains 1 or 2 heteroatoms selected from N, O and S,
    • wherein said phenyl, heterocycloalkyl and heteroaryl are bound directly or via a C1-C2-alkylene linker,
    • and wherein the cyclic moieties of Ra carry 1 or 2 substituents selected from halogen and C1-C2-haloalkyl,
    • and wherein the cyclic moieties of Ra further carry 0, 1, 2 or up to the maximum number of identical or different groups Rb selected from CN, NH2, NO2, C1-C4-alkyl and —O—C1-C4-alkyl;
  • n is an integer selected from 0, 1, 2 and 3;
  • and in form or stereoisomers and tautomers thereof, and the N-oxides and the agriculturally acceptable salts thereof.


According to a further embodiment, R1 is O and R2 is N, which compounds are of formula I.1:




embedded image - 1.1.


According to a further embodiment, R1 is O and R2 is CH, which compounds are of formula I.2:




embedded image - I.2.


According to a further embodiment, R1 is NH and R2 is N, which compounds are of formula I.3:




embedded image - I.3.


Preferably, R3 of compounds I is one of the followin radicals 3-1 to 3-6:










No.
R3




3-1
CH3


3-2
OCH3














No.
R3




3-3
CHF2


3-4
C3H5














No.
R3




3-5
CH═CH2


3-6
CH2CH═C(CH3)2






Even more preferably R3 is CH3, OCH3, CHF2 or C3H5, in particular CH3.


Particularly preferred embodiments of the invention relate to compounds I, wherein the R4 is one of the following radicals 4-1 to 4-8:










No.
R4




4-1
CH3


4-2
C2H5


4-3
CH2OCH3














No.
R4




4-4
CH2CF3


4-5
CHF2


4-6
CH2C3H5














No.
R4




4-7
C═CH


4-8
C═CCH3






Particularly preferred embodiments of the invention relate to compounds I, wherein the Ra is selected of one of the following radicals a-1 to a-7:










No.
Ra




a-1
F


a-2
Cl


a-3
Br














No.
Ra




a-4
CHF2


a-5
CF3


a-6
CH2CF3














No.
Ra




a-7
C═CCF3






According to a further embodiment, n is 1. More preferably, Ra is in ortho-position (2-Ra), which compounds are of formula I.A:




embedded image - I.A


wherein even more preferably R1 is O and R2 is N. According to a further embodiment, Ra is in meta-position (3-Ra), which compounds are of formula I.B:




embedded image - I.B


wherein even more preferably R1 is O and R2 is N.


According to a further embodiment, n is 2. More preferably, n is 2 and the two Ra substituents are both in meta -position (3,5-Ra), which compounds are of formula I.C:




embedded image - I.C


wherein even more preferably R2 is N. According to a further embodiment, n is 2 and the two Ra substituents are both in ortho-position (2,6-Ra), which compounds are of formula I.D:




embedded image - I.D


wherein even more preferably R2 is N. According to a further embodiment, n is 2 and the two Ra substituents are in ortho- and meta-position, which compounds are of formula I.E:




embedded image - I.E


, wherein even more preferably R2 is N. According to a further embodiment, n is 2 and the two Ra substituents are in ortho- and para-position, which compounds are of formula I.F:




embedded image - I.F


wherein even more preferably R2 is N.


In an embodiment, compounds I are of formula 1.3 and n, Ra, R3 and R4 are as per any row of per Table A below, which compounds are named I.3-A-1 to I.3-A-131.


In another embodiment, compounds I are of formula I.2 and n, Ra, R3 and R4 are as per any row of Table A below, which compounds are named I.2-A-1 to I.2-A-131.


In an embodiment, compounds I are of formula I.1 and n, Ra, R3 and R4 are as per any row of Table A below, which compounds are named I.1-A-1 to I.1-A-131.





TABLE A








No.
n
Ra
R3
R4




A-1
0
-
CH3
CH3


A-2
1
2-F
CH3
CH3


A-3
1
2-Cl
CH3
CH3


A-4
1
2-Br
CH3
CH3


A-5
1
2-CHF2
CH3
CH3


A-6
1
2-CF3
CH3
CH3


A-7
1
2-CH2CF3
CH3
CH3


A-8
1
2—C≡CCF3
CH3
CH3


A-9
1
3-F
CH3
CH3


A-10
1
3-Cl
CH3
CH3


A-11
1
3-Br
CH3
CH3


A-12
1
3-CHF2
CH3
CH3


A-13
1
3-CF3
CH3
CH3


A-14
1
3-CH2CF3
CH3
CH3


A-15
1
3—C≡CCF3
CH3
CH3


A-16
1
4-F
CH3
CH3


A-17
1
4-Cl
CH3
CH3


A-18
1
4-Br
CH3
CH3


A-19
1
4-CHF2
CH3
CH3


A-20
1
4-CF3
CH3
CH3


A-21
1
4-CH2CF3
CH3
CH3


A-22
1
4—C≡CCF3
CH3
CH3


A-23
0
-
CH3
C2H5


A-24
1
2-F
CH3
C2H5


A-25
1
2-Cl
CH3
C2H5


A-26
1
2-Br
CH3
C2H5


A-27
1
2-CHF2
CH3
C2H5


A-28
1
2-CF3
CH3
C2H5


A-29
1
2-CH2CF3
CH3
C2H5


A-30
1
2—C≡CCF3
CH3
C2H5


A-31
1
3-F
CH3
C2H5


A-32
1
3-Cl
CH3
C2H5


A-33
1
3-Br
CH3
C2H5


A-34
1
3-CHF2
CH3
C2H5


A-35
1
3-CF3
CH3
C2H5


A-36
1
3-CH2CF3
CH3
C2H5


A-37
1
3—C≡CCF3
CH3
C2H5


A-38
1
4-F
CH3
C2H5


A-39
1
4-Cl
CH3
C2H5


A-40
1
4-Br
CH3
C2H5


A-41
1
4-CHF2
CH3
C2H5


A-42
1
4-CF3
CH3
C2H5


A-43
1
4-CH2CF3
CH3
C2H5


A-44
1
4—C≡CCF3
CH3
C2H5


A-45
0
-
CH3
CH2CF3


A-46
1
2-F
CH3
CH2CF3


A-47
1
2-Cl
CH3
CH2CF3


A-48
1
2-Br
CH3
CH2CF3


A-49
1
2-CHF2
CH3
CH2CF3


A-50
1
2-CF3
CH3
CH2CF3


A-51
1
2-CH2CF3
CH3
CH2CF3


A-52
1
2—C≡CCF3
CH3
CH2CF3


A-53
1
3-F
CH3
CH2CF3


A-54
1
3-Cl
CH3
CH2CF3


A-55
1
3-Br
CH3
CH2CF3


A-56
1
3-CHF2
CH3
CH2CF3


A-57
1
3-CF3
CH3
CH2CF3


A-58
1
3-CH2CF3
CH3
CH2CF3


A-59
1
3—C≡CCF3
CH3
CH2CF3


A-60
1
4-F
CH3
CH2CF3


A-61
1
4-Cl
CH3
CH2CF3


A-62
1
4-Br
CH3
CH2CF3


A-63
1
4-CHF2
CH3
CH2CF3


A-64
1
4-CF3
CH3
CH2CF3


A-65
1
4-CH2CF3
CH3
CH2CF3


A-66
1
4—C≡CCF3
CH3
CH2CF3


A-67
0
-
CH3
CH2OCH3


A-68
1
2-F
CH3
CH2OCH3


A-69
1
2-Cl
CH3
CH2OCH3


A-70
1
2-Br
CH3
CH2OCH3


A-71
1
2-CHF2
CH3
CH2OCH3


A-72
1
2-CF3
CH3
CH2OCH3


A-73
1
2-CH2CF3
CH3
CH2OCH3


A-74
1
2—C≡CCF3
CH3
CH2OCH3


A-75
1
3-F
CH3
CH2OCH3


A-76
1
3-Cl
CH3
CH2OCH3


A-77
1
3-Br
CH3
CH2OCH3


A-78
1
3-CHF2
CH3
CH2OCH3


A-79
1
3-CF3
CH3
CH2OCH3


A-80
1
3-CH2CF3
CH3
CH2OCH3


A-81
1
3—C≡CCF3
CH3
CH2OCH3


A-82
1
4-F
CH3
CH2OCH3


A-83
1
4-Cl
CH3
CH2OCH3


A-84
1
4-Br
CH3
CH2OCH3


A-85
1
4-CHF2
CH3
CH2OCH3


A-86
1
4-CF3
CH3
CH2OCH3


A-87
1
4-CH2CF3
CH3
CH2OCH3


A-88
1
4—C≡CCF3
CH3
CH2OCH3


A-89
0
-
CH3
CHF2


A-90
1
2-F
CH3
CHF2


A-91
1
2-Cl
CH3
CHF2


A-92
1
2-Br
CH3
CHF2


A-93
1
2-CHF2
CH3
CHF2


A-94
1
2-CF3
CH3
CHF2


A-95
1
2—C≡CCF3
CH3
CHF2


A-96
1
3-F
CH3
CHF2


A-97
1
3-Cl
CH3
CHF2


A-98
1
3-Br
CH3
CHF2


A-99
1
3-CHF2
CH3
CHF2


A-100
1
3-CF3
CH3
CHF2


A-101
1
3-CH2CF3
CH3
CHF2


A-102
1
3—C≡CCF3
CH3
CHF2


A-103
1
4-F
CH3
CHF2


A-104
1
4-Cl
CH3
CHF2


A-105
1
4-Br
CH3
CHF2


A-106
1
4-CHF2
CH3
CHF2


A-107
1
4-CF3
CH3
CHF2


A-108
1
4-CH2CF3
CH3
CHF2


A-109
1
4—C≡CCF3
CH3
CHF2


A-110
0
-
CH3
CH2C3H5


A-111
1
2-F
CH3
CH2C3H5


A-112
1
2-Cl
CH3
CH2C3H5


A-113
1
2-Br
CH3
CH2C3H5


A-114
1
2-CHF2
CH3
CH2C3H5


A-115
1
2-CF3
CH3
CH2C3H5


A-116
1
2-CH2CF3
CH3
CH2C3H5


A-117
1
2—C≡CCF3
CH3
CH2C3H5


A-118
1
3-F
CH3
CH2C3H5


A-119
1
3-Cl
CH3
CH2C3H5


A-120
1
3-Br
CH3
CH2C3H5


A-121
1
3-CHF2
CH3
CH2C3H5


A-122
1
3-CF3
CH3
CH2C3H5


A-123
1
3-CH2CF3
CH3
CH2C3H5


A-124
1
3—C≡CCF3
CH3
CH2C3H5


A-125
1
4-F
CH3
CH2C3H5


A-126
1
4-Cl
CH3
CH2C3H5


A-127
1
4-Br
CH3
CH2C3H5


A-128
1
4-CHF2
CH3
CH2C3H5


A-129
1
4-CF3
CH3
CH2C3H5


A-130
1
4-CH2CF3
CH3
CH2C3H5


A-131
1
4—C≡CCF3
CH3
CH2C3H5






Synthesis

The compounds can be obtained by various routes in analogy to prior art processes known (e.g EP 463488) and, advantageously, by the synthesis shown in the following schemes 1 to 4 and in the experimental part of this application.


A suitable method to prepare compounds I is illustrated in Scheme 1. Scheme 1:




embedded image




embedded image


It starts with the conversion of a ketone to the corresponding oxime using hydxroxylamine hydrochloride and a base such as pyridine, sodium hydroxide or sodium acetate in polar solvents such as methanol, methanol-water mixture, or ethanol at reaction temperatures of 60 to 100° C., preferably at about 65° C. In cases where a E/Z mixture was obtained, the isomers could be separated by purifycation techniques known in art (e.g. column chromatography, crystallization, distillation etc.). Then, coupling with the intermediate IV, wherein X is a leaving group such as halogen, toluene- and methanesulfonates, preferably X is Cl or Br, is carried out under basic conditions using e.g. sodium hydride, cesium carbonate or potassium carbonate as a base and using an organic solvent such as dimethyl formamide (DMF) or acetonitrile, preferably cesium carbonate as base and acetonitrile as solvent at room temperature (RT) of about 24° C. . The ester compound I wherein R1 is O can be converted to the amide of formula I wherein R1 is NH by reaction with methyl amine (preferably 40% aq. solution) using tetrahydrofuran (THF) as solvent at RT.


Another general method to prepare the compounds I is depicted in Scheme 2. Scheme 2:




embedded image


Intermediate IV is reacted with N-hydroxysuccimide VI, using a base such as triethylamine in DMF. The reaction temperature is usually 50 to 70° C. preferably about 70° C. Conversion to the correspondding O-benzylhydroxyl amine, intermediate VIII, was achieved through removal of the phthalimide group, preferably using hydrazine hydrate in methanol as solvent at 25° C. Alternatively, removal of the phthalimide group using methyl amine in methanol as solvent at 25° C. can provide intermediate IX. Intermediate VIII and intermediate IX, respectively can be condensed with ketones using acetic acid or pyridine in methanol as solvent at temperature of 50 to 65° C. Alternatively, the condensation could also carried out with titanium (IV) ethoxide (Ti(OEt)4) using THF as solvent at about 70° C. The desired product is usually accompanied by an undesired isomer, which can be removed e.g by column chromatography, crystallization.


A general method for preparation of intermediate IV is shown in Scheme 3. Scheme 3:




embedded image


Compound XI could be obtained from X by lithium-halogen exchange or by generating Grignard reagent and further reaction with dimethyl oxalate or chloromethyl oxalate in presence of a solvent. The preferred solvent is THF, 2-methyl-THF and the temperature can be between -70 to -78° C. Conversion of intermediate XI to intermediate XII can be achieved using N-methylhydroxylamine hydrochloride and a base such as pyridine or sodium acetate in polar solvents such as methanol. The reaction temperature is preferably about 65° C. An E/Z mixture is usually obtained, the isomers can be separated by purification techniques known in art (e.g. column chromatography, crystallization). Bromination of intermediate XII provides the desired intermediate compounds IV, wherein R1 is O and R2 = N. This reaction of intermediate XII with N-bromosuccinimide in solvents such as carbon tetrachloride, chlorobenzene, acetonitrile, using radical initiators such as 1,1′-azobis (cyclohexanecarbonitrile) or azobisisobutyronitrile and is carried out at temperatures of 70 to 100° C. The preferred radical initiator is 1,1′-azobis (cyclohexanecarbonitrile), preferred solvent chlorobenzene and preferred temperature 80° C.


The synthesis of compounds containing different substituents R3 follows similar sequence as in Scheme 3, wherein R3 is bromo. Coupling of intermediate III with intermediate IV, wherein R3 is bromo, provides compounds I as described above. Using standard chemical reactions, such as Suzuki or Stille reaction, the bromo group can be converted e.g. to other R3 substituents such as cycloalkyl, alkoxy and alkenyl. Additional transformations e.g. of ethenyl provide compounds I with other R3 substituents such as ethyl, CN and haloalkyl.


Most of the ketones of general formula II were commercially available, however for the ones which were not commercially available, preparation of these was carried out in house using methods known in prior art. Scheme 4 depicts various methods known in literature for the synthesis of these ketones. Scheme 4:




embedded image


The ketone II can be obtained from the corresponding halogen bearing precursors XIV, wherein X is preferably bromine or iodine. Lithium-halogen exchange (J Org Chem, 1998, 63 (21), 7399-7407) in compound XIII using n-butyllithium or synthesis of the corresponding Grignard reagent (Nature Comm, 2017, 8(1), 1-7) using THF as solvent, and subsequent reaction with N-methoxy-N-methylacetamide at about -70 to -78° C. can provide the ketone II. Alternatively, the coupling reaction of compound XIV and tributyl(1-ethoxyvinyl)stannane in presence of a transition metal catalyst, preferably palladium, with suitable ligands in a solvent such as dioxane and at a reaction temperature of about 100° C., followed by treatment with 1N HCl can provide ketone II (Org Lett, 2016, 18(7), 1630-1633, WO 2018/115380). Reaction of XIV with 1,4-butanediol vinyl ether in the presence of transition metal catalyst, preferably palladium with suitable ligands and solvent such as 1,2-propane diol and base such as sodium carbonate and reaction temperature of about 120° C. followed by treatment with 1N HCl can provide ketone II (Chem A Eur J, 2008, 14(18), 5555-5566). Another method uses acid compounds XV, which can be converted to the corresponding Weinreb amide or carboxylic ester XVII and subsequent reaction with methylmagnesium bromide (MeMgBr) in solvent such as THF and temperatures of -78 to 0° C., preferably 0° C., to provide ketone II. Another method uses the reaction of nitrile XVI with MeMgBr which is carried out in solvent such as THF or toluene, preferably THF, and reaction temperature is 25 to 60° C., preferably 60° C., followed by treatment with 1N HCl (Eur J Med Chem, 2015, 102, 582-593).


The compounds I and the compositions thereof, respectively, are suitable as fungicides effective against a broad spectrum of phytopathogenic fungi, including soil-borne fungi, in particular from the classes of Plasmodiophoromycetes, Peronosporomycetes (syn. Oomycetes), Chytridiomycetes, Zygomycetes, Ascomycetes, Basidiomycetes, and Deuteromycetes (syn. Fungi imperfecti). They can be used in crop protection as foliar fungicides, fungicides for seed dressing, and soil fungicides.


The compounds I and the compositions thereof are preferably useful in the control of phytopathogenic fungi on various cultivated plants, such as cereals, e. g. wheat, rye, barley, triticale, oats, or rice; beet, fruits, leguminous plants such as soybean, oil plants, cucurbits, fiber plants, citrus fruits, vegetables, lauraceous plants, energy and raw material plants, corn; tobacco; nuts; coffee; tea; bananas; vines (table grapes and grape juice grape vines); natural rubber plants; or ornamental and forestry plants; on the plant propagation material, such as seeds; and on the crop material of these plants.


According to the invention all of the above cultivated plants are understood to comprise all species, subspecies, variants, varieties and/or hybrids which belong to the respective cultivated plants, including but not limited to winter and spring varieties, in particular in cereals such as wheat and barley, as well as oilseed rape, e.g. winter wheat, spring wheat, winter barley etc.


Corn is also known as Indian corn or maize (Zea mays) which comprises all kinds of corn such as field corn and sweet corn. According to the invention all soybean cultivars or varieties are comprised, in particular indeterminate and determinate cultivars or varieties.


The term “cultivated plants” is to be understood as including plants which have been modified by mutagenesis or genetic engineering to provide a new trait to a plant or to modify an already present trait.


The compounds I and compositions thereof, respectively, are particularly suitable for controlling the following causal agents of plant diseases: rusts on soybean and cereals (e.g. Phakopsora pachyrhizi and P. meibomiae on soybean; Puccinia tritici and P. striiformis on wheat); molds on specialty crops, soybean, oil seed rape and sunflowers (e.g. Botrytis cinerea on strawberries and vines, Sclerotinia sclerotiorum, S. minor and S. rolfsii on oil seed rape, sunflowers and soybean); Fusarium diseases on cereals (e.g. Fusarium culmorum and F. graminearum on wheat); downy mildews on specialty crops (e.g. Plasmopara viticola on vines, Phytophthora infestans on potatoes); powdery mildews on specialty crops and cereals (e.g. Uncinula necator on vines, Erysiphe spp. on various specialty crops, Blumeria graminis on cereals); and leaf spots on cereals, soybean and corn (e.g. Septoria tritici and S. nodorum on cereals, S. glycines on soybean, Cercospora spp. on corn and soybean).


The compounds I and compositions thereof, respectively, are also suitable for controlling harmful microorganisms in the protection of stored products or harvest, and in the protection of materials.


The compounds I are employed as such or in form of compositions by treating the fungi, the plants, plant propagation materials, such as seeds; soil, surfaces, materials, or rooms to be protected from fungal attack with a fungicidally effective amount of the active substances. The application can be carried out both before and after the infection of the plants, plant propagation materials, such as seeds; soil, surfaces, materials or rooms by the fungi.


An agrochemical composition comprises a fungicidally effective amount of a compound I. The term “fungicidally effective amount” denotes an amount of the composition or of the compounds I, which is sufficient for controlling harmful fungi on cultivated plants or in the protection of stored products or harvest or of materials and which does not result in a substantial damage to the treated plants, the treated stored products or harvest, or to the treated materials. Such an amount can vary in a broad range and is dependent on various factors, such as the fungal species to be controlled, the treated cultivated plant, stored product, harvest or material, the climatic conditions and the specific compound I used.


Plant propagation materials may be treated with compounds I as such or a composition comprising at least one compound I prophylactically either at or before planting or transplanting.


The user applies the agrochemical composition usually from a predosage device, a knapsack sprayer, a spray tank, a spray plane, or an irrigation system. Usually, the agrochemical composition is made up with water, buffer, and/or further auxiliaries to the desired application concentration and the ready-to-use spray liquor or the agrochemical composition according to the invention is thus obtained. Usually, 20 to 2000 liters, preferably 50 to 400 liters, of the ready-to-use spray liquor are applied per hectare of agricultural useful area.


The compounds I, their N-oxides and salts can be converted into customary types of agrochemical compositions, e. g. solutions, emulsions, suspensions, dusts, powders, pastes, granules, pressings, capsules, and mixtures thereof. Examples for composition types (see “Catalogue of pesticide formulation types and international coding system”, Technical Monograph No. 2, 6th Ed. May 2008, CropLife International) are suspensions (e. g. SC, OD, FS), emulsifiable concentrates (e. g. EC), emulsions (e. g. EW, EO, ES, ME), capsules (e. g. CS, ZC), pastes, pastilles, wettable powders or dusts (e. g. WP, SP, WS, DP, DS), pressings (e. g. BR, TB, DT), granules (e. g. WG, SG, GR, FG, GG, MG), insecticidal articles (e. g. LN), as well as gel formulations for the treatment of plant propagation materials, such as seeds (e. g. GF). The compositions are prepared in a known manner, such as described by Mollet and Grubemann, Formulation technology, Wiley VCH, Weinheim, 2001; or by Knowles, New developments in crop protection product formulation, Agrow Reports DS243, T&F Informa, London, 2005. The invention also relates to agrochemical compositions comprising an auxiliary and at least one compound I. Suitable auxiliaries are solvents, liquid carriers, solid carriers or fillers, surfactants, dispersants, emulsifiers, wetters, adjuvants, solubilizers, penetration enhancers, protective colloids, adhesion agents, thickeners, humectants, repellents, attractants, feeding stimulants, compatibilizers, bactericides, anti-freezing agents, anti-foaming agents, colorants, tackifiers and binders.


The agrochemical compositions generally comprise between 0.01 and 95 %, preferably between 0.1 and 90%, more preferably between 1 and 70 %, and in particular between 10 and 60 %, by weight of active substance (e.g. at least one compound I). Further, the agrochemical compositions generally comprise between 5 and 99.9 %, preferably between 10 and 99.9 %, more preferably between 30 and 99 %, and in particular between 40 and 90 %, by weight of at least one auxiliary.


When employed in plant protection, the amounts of active substances applied are, depending on the kind of effect desired, from 0.001 to 2 kg per ha, preferably from 0.005 to 2 kg per ha, more preferably from 0.05 to 0.9 kg per ha, and in particular from 0.1 to 0.75 kg per ha.


In treatment of plant propagation materials, such as seeds, e. g. by dusting, coating, or drenching, amounts of active substance of generally from 0.1 to 1000 g, preferably from 1 to 1000 g, more preferably from 1 to 100 g and most preferably from 5 to 100 g, per 100 kg of plant propagation material (preferably seeds) are required.


Various types of oils, wetters, adjuvants, fertilizers, or micronutrients, and further pesticides (e. g. fungicides, growth regulators, herbicides, insecticides, safeners) may be added to the compounds I or the compositions thereof as premix, or, not until immediately prior to use (tank mix). These agents can be admixed with the compositions according to the invention in a weight ratio of 1:100 to 100:1, preferably 1:10 to 10:1.


Mixing the compounds I or the compositions comprising them in the use form as fungicides with other fungicides results in many cases in an expansion of the fungicidal spectrum of activity or in a prevention of fungicide resistance development. Furthermore, in many cases, synergistic effects are obtained (synergistic mixtures).


The following list of pesticides II, in conjunction with which the compounds I can be used, is intended to illustrate the possible combinations but does not limit them:

  • A) Respiration inhibitors
    • Inhibitors of complex III at Qo site: azoxystrobin (A.1.1), coumethoxystrobin (A.1.2), coumoxystrobin (A.1.3), dimoxystrobin (A.1.4), enestroburin (A.1.5), fenaminstrobin (A.1.6), fenoxystrobin/flufenoxystrobin (A.1.7), fluoxastrobin (A.1.8), kresoxim-methyl (A.1.9), mandestrobin (A.1.10), metominostrobin (A.1.11), orysastrobin (A.1.12), picoxystrobin (A.1.13), pyraclostrobin (A.1.14), pyrametostrobin (A.1.15), pyraoxystrobin (A.1.16), trifloxy-strobin (A.1.17), 2-(2-(3-(2,6-dichlorophenyl)-1-methyl-allylideneaminooxymethyl)-phenyl)-2-methoxyimino-N-methyl-acetamide (A.1.18), pyribencarb (A.1.19), triclopyricarb/chloro-dincarb (A.1.20), famoxadone (A.1.21), fenamidone (A.1.21), methyl—N—[2-[(1,4-dimethyl-5-phenyl-pyrazol-3-yl)oxylmethyl]phenyl]—N—methoxy-carbamate (A.1.22), metyltetraprole (A.1.25), (Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]-oxy-2-methoxyimino-N,3-dimethyl-pent-3-enamide (A.1.34), (Z,2E)-5-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-N,3-dimethyl-pent-3-enamide (A.1.35), pyriminostrobin (A.1.36), bifujunzhi (A.1.37), 2-(ortho-((2,5-dimethylphenyl-oxymethylen)phenyl)-3-methoxy-acrylic acid methylester (A.1.38);
    • inhibitors of complex III at Qi site: cyazofamid (A.2.1), amisulbrom (A.2.2), [(6S,7R,8R)-8-benzyl-3-[(3-hydroxy-4-methoxy-pyridine-2-carbonyl)amino]-6-methyl-4,9-di-oxo-1,5-dioxonan-7-yl] 2-methylpropanoate (A.2.3), fenpicoxamid (A.2.4), florylpicoxamid (A.2.5), metarylpicoxamid (A.2.6);
    • inhibitors of complex II: benodanil (A.3.1), benzovindiflupyr (A.3.2), bixafen (A.3.3), boscalid (A.3.4), carboxin (A.3.5), fenfuram (A.3.6), fluopyram (A.3.7), flutolanil (A.3.8), fluxapyroxad (A.3.9), furametpyr (A.3.10), isofetamid (A.3.11), isopyrazam (A.3.12), mepronil (A.3.13), oxycarboxin (A.3.14), penflufen (A.3.15), penthiopyrad (A.3.16), pydiflumetofen (A.3.17), pyraziflumid (A.3.18), sedaxane (A.3.19), tecloftalam (A.3.20), thifluzamide (A.3.21), inpyrfluxam (A.3.22), pyrapropoyne (A.3.23), fluindapyr (A.3.28), N—[2-[2-chloro-4-(trifluoromethyl)phenoxy]phenyl]-3-(difluoromethyl)-5-fluoro-1-methyl-pyrazole-4-carboxamide (A.3.29), methyl (E)-2-[2-[(5-cyano-2-methyl-phenoxy)methyl]phenyl]-3-methoxy-prop-2-enoate (A.3.30), isoflucypram (A.3.31), 2-(difluoromethyl)-N-(1,1,3-trimethyl-indan-4-yl)-pyridine-3-carboxamide (A.3.32), 2-(difluoromethyl)—N—[(3R)-1,1,3-trimethylindan-4-yl]-pyridine-3-carboxamide (A.3.33), 2-(difluoromethyl)-N-(3-ethyl-1,1-dimethyl-indan-4-yl)-pyridine-3-carboxamide (A.3.34), 2-(difluoromethyl)—N—[(3R)-3-ethyl-1,1-dimethyl-indan-4-yl]-pyridine-3-carboxamide (A.3.35), 2-(difluoromethyl)-N-(1,1-dimethyl-3-propyl-indan-4-yl)pyridine-3-carboxamide (A.3.36), 2-(difluoromethyl)—N—[(3R)-1,1-dimethyl-3-propyl-indan-4-yl]-pyridine-3-carboxamide (A.3.37), 2-(difluoromethyl)-N-(3-isobutyl-1,1-dimethyl-indan-4-yl)-pyridine-3-carboxamide (A.3.38), 2-(difluoromethyl)—N—[(3R)-3-isobutyl-1,1-dimethyl-indan-4-yl]pyridine-3-carboxamide (A.3.39) cyclobutrifluram (A.3.24);
    • other respiration inhibitors: diflumetorim (A.4.1); nitrophenyl derivates: binapacryl (A.4.2), dinobuton (A.4.3), dinocap (A.4.4), fluazinam (A.4.5), meptyldinocap (A.4.6), ferimzone (A.4.7); organometal compounds: fentin salts, e. g. fentin-acetate (A.4.8), fentin chloride (A.4.9) or fentin hydroxide (A.4.10); ametoctradin (A.4.11); silthiofam (A.4.12);
  • B) Sterol biosynthesis inhibitors (SBI fungicides)
    • C14 demethylase inhibitors: triazoles: azaconazole (B.1.1), bitertanol (B.1.2), bromu-conazole (B.1.3), cyproconazole (B.1.4), difenoconazole (B.1.5), diniconazole (B.1.6), diniconazole-M (B.1.7), epoxiconazole (B.1.8), fenbuconazole (B.1.9), fluquinconazole (B.1.10), flusilazole (B.1.11), flutriafol (B.1.12), hexaconazole (B.1.13), imibenconazole (B.1.14), ipconazole (B.1.15), metconazole (B.1.17), myclobutanil (B.1.18), oxpoconazole (B.1.19), paclobutrazole (B.1.20), penconazole (B.1.21), propiconazole (B.1.22), prothio-conazole (B.1.23), simeconazole (B.1.24), tebuconazole (B.1.25), tetraconazole (B.1.26), triadimefon (B.1.27), triadimenol (B.1.28), triticonazole (B.1.29), uniconazole (B.1.30), 2-(2,4-difluorophenyl)-1,1-difluoro-3-(tetrazol-1-yl)-1-[5-[4-(2,2,2-trifluoroethoxy)phenyl]-2-pyridyl]propan-2-ol (B.1.31), 2-(2,4-difluorophenyl)-1,1-difluoro-3-(tetrazol-1-yl)-1-[5-[4-(tri-fluoromethoxy)phenyl]-2-pyridyl]propan-2-ol (B.1.32), fluooxytioconazole (B.1.33), ipfentrifluconazole (B.1.37), mefentrifluconazole (B.1.38), (2R)-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1,2,4-triazol-1-yl)propan-2-ol, (2S)-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1,2,4-triazol-1-yl)propan-2-ol, 2-(chloromethyl)-2-methyl-5-(p-tolylmethyl)-1-(1,2,4-triazol-1-ylmethyl)cyclopentanol (B.1.43); imidazoles: imazalil (B.1.44), pefurazoate (B.1.45), prochloraz (B.1.46), triflumizol (B.1.47); pyrimidines, pyridines, piperazines: fena1rimol (B.1.49), pyrifenox (B.1.50), triforine (B.1.51), [3-(4-chloro-2-fluoro-phenyl)-5-(2,4-difluorophenyl)isoxazol-4-yl]-(3-pyridyl)methanol (B.1.52), 4-[[6-[2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1,2,4-triazol-1-yl)propyl]-3-pyridyl]oxy]benzonitrile (B.1.53), 2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol (B.1.54), 2-[6-(4-chlorophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol (B.1.55);
    • Delta14-reductase inhibitors: aldimorph (B.2.1), dodemorph (B.2.2), dodemorph-acetate (B.2.3), fenpropimorph (B.2.4), tridemorph (B.2.5), fenpropidin (B.2.6), piperalin (B.2.7), spiroxamine (B.2.8);
    • Inhibitors of 3-keto reductase: fenhexamid (B.3.1);
    • Other Sterol biosynthesis inhibitors: chlorphenomizole (B.4.1);
  • C) Nucleic acid synthesis inhibitors
    • phenylamides or acyl amino acid fungicides: benalaxyl (C.1.1), benalaxyl-M (C.1.2), kiralaxyl (C.1.3), metalaxyl (C.1.4), metalaxyl-M (C.1.5), ofurace (C .1.6), oxadixyl (C.1.7);
    • other nucleic acid synthesis inhibitors: hymexazole (C.2.1), octhilinone (C.2.2), oxolinic acid (C.2.3), bupirimate (C.2.4), 5-fluorocytosine (C.2.5), 5-fluoro-2-(p-tolylmethoxy)pyrimidin-4-amine (C.2.6), 5-fluoro-2-(4-fluorophenylmethoxy)pyrimidin-4-amine (C.2.7), 5-fluoro-2-(4-chlorophenylmethoxy)pyrimidin-4 amine (C.2.8);
  • D) Inhibitors of cell division and cytoskeleton
    • tubulin inhibitors: benomyl (D.1.1), carbendazim (D.1.2), fuberidazole (D1.3), thiabendazole (D.1.4), thiophanate-methyl (D.1.5), pyridachlometyl (D.1.6), N-ethyl-2-[(3-ethynyl-8-methyl-6-quinolyl)oxy]butanamide (D.1.8), N-ethyl-2-[(3-ethynyl-8-methyl-6-quinolyl)oxy]-2-methyl-sulfanyl-acetamide (D.1.9), 2-[(3-ethynyl-8-methyl-6-quinolyl)oxy]—N—(2-fluoroethyl)butanamide (D.1.10), 2-[(3-ethynyl-8-methyl-6-quinolyl)oxy]—N—(2-fluoroethyl)-2-methoxy-acetamide (D.1.11), 2-[(3-ethynyl-8-methyl-6-quinolyl)oxy]—N—propyl-butanamide (D.1.12), 2-[(3-ethynyl-8-methyl-6-quinolyl)oxy]-2-methoxy-N-propyl-acetamide (D.1.13), 2-[(3-ethynyl-8-methyl-6-quinolyl)oxy]-2-methylsulfanyl-N-propyl-acetamide (D.1.14), 2-[(3-ethynyl-8-methyl-6-quinolyl)oxy]—N—(2-fluoroethyl)-2-methylsulfanyl-acetamide (D.1.15), 4-(2-bromo-4-fluorophenyl)-N-(2-chloro-6-fluoro-phenyl)-2,5-dimethyl-pyrazol-3-amine (D.1.16);
    • other cell division inhibitors: diethofencarb (D.2.1), ethaboxam (D.2.2), pencycuron (D.2.3), fluopicolide (D.2.4), zoxamide (D.2.5), metrafenone (D.2.6), pyriofenone (D.2.7), phenamacril (D.2.8);
  • E) Inhibitors of amino acid and protein synthesis
    • methionine synthesis inhibitors: cyprodinil (E.1.1), mepanipyrim (E.1.2), pyrimethanil (E.1.3);
    • protein synthesis inhibitors: blasticidin-S (E.2.1), kasugamycin (E.2.2), kasugamycin hydrochloride-hydrate (E.2.3), mildiomycin (E.2.4), streptomycin (E.2.5), oxytetracyclin (E.2.6);
  • F) Signal transduction inhibitors
    • MAP / histidine kinase inhibitors: fluoroimid (F.1.1), iprodione (F.1.2), procymidone (F.1.3), vinclozolin (F.1.4), fludioxonil (F.1.5);
    • G protein inhibitors: quinoxyfen (F.2.1);
  • G) Lipid and membrane synthesis inhibitors
    • Phospholipid biosynthesis inhibitors: edifenphos (G.1.1), iprobenfos (G.1.2), pyrazophos (G.1.3), isoprothiolane (G.1.4);
    • lipid peroxidation: dicloran (G.2.1), quintozene (G.2.2), tecnazene (G.2.3), tolclofos-methyl (G.2.4), biphenyl (G.2.5), chloroneb (G.2.6), etridiazole (G.2.7), zinc thiazole (G.2.8);
    • phospholipid biosynthesis and cell wall deposition: dimethomorph (G.3.1), flumorph (G.3.2), mandipropamid (G.3.3), pyrimorph (G.3.4), benthiavalicarb (G.3.5), iprovalicarb (G.3.6), valifenalate (G.3.7);
    • compounds affecting cell membrane permeability and fatty acides: propamocarb (G.4.1);
    • inhibitors of oxysterol binding protein: oxathiapiprolin (G.5.1), fluoxapiprolin (G.5.3), 4-[1-[2-[3-(difluoromethyl)-5-methyl-pyrazol-1-yl]acetyl]-4-piperidyl]—N—tetralin-1-yl-pyridine-2-carboxamide (G.5.4), 4-[1-[2-[3,5-bis(difluoromethyl)pyrazol-1-yl]acetyl]-4-piperidyl]—N—tetralin-1-yl-pyridine-2-carboxamide (G.5.5), 4-[1-[2-[3-(difluoromethyl)-5-(trifluoromethyl)pyrazol-1-yl]acetyl]-4-piperidyl]—N—tetralin-1-yl-pyridine-2-carboxamide (G.5.6), 4-[1-[2-[5-cyclopropyl-3-(difluoromethyl)pyrazol-1-yl]acetyl]-4-piperidyl]—N—tetralin-1-yl-pyridine-2-carboxamide (G.5.7), 4-[1-[2-[5-methyl-3-(trifluoromethyl)pyrazol-1-yl]acetyl]-4-piperidyl]—N—tetralin-1-yl-pyridine-2-carboxamide (G.5.8), 4-[1-[2-[5-(difluoromethyl)-3-(trifluoromethyl)pyrazol-1-yl]acetyl]-4-piperidyl]—N—tetralin-1-yl-pyridine-2-carboxamide (G.5.9), 4-[1-[2-[3,5-bis(trifluoromethyl)pyrazol-1-yl]acetyl]-4-piperidyl]—N—tetralin-1-yl-pyridine-2-carboxamide (G.5.10), (4-[1-[2-[5-cyclopropyl-3-(trifluoromethyl)pyrazol-1-yl]acetyl]-4-piperidyl]—N—tetralin-1-yl-pyridine-2-carboxamide (G.5.11);
  • H) Inhibitors with Multi Site Action
    • inorganic active substances: Bordeaux mixture (H.1.1), copper (H.1.2), copper acetate (H.1.3), copper hydroxide (H.1.4), copper oxychloride (H.1.5), basic copper sulfate (H.1.6), sulfur (H.1.7);
    • thio- and dithiocarbamates: ferbam (H.2.1), mancozeb (H.2.2), maneb (H.2.3), metam (H.2.4), metiram (H.2.5), propineb (H.2.6), thiram (H.2.7), zineb (H.2.8), ziram (H.2.9);
    • organochlorine compounds: anilazine (H.3.1), chlorothalonil (H.3.2), captafol (H.3.3), captan (H.3.4), folpet (H.3.5), dichlofluanid (H.3.6), dichlorophen (H.3.7), hexachlorobenzene (H.3.8), pentachlorphenole (H.3.9) and its salts, phthalide (H.3.10), tolylfluanid (H.3.11);
    • guanidines and others: guanidine (H.4.1), dodine (H.4.2), dodine free base (H.4.3), guazatine (H.4.4), guazatine-acetate (H.4.5), iminoctadine (H.4.6), iminoctadine-triacetate (H.4.7), iminoctadine-tris(albesilate) (H.4.8), dithianon (H.4.9), 2,6-dimethyl-1H,5H-[1,4]di-thiino[2,3-c:5,6-c′]dipyrrole-1,3,5,7(2H,6H)-tetraone (H.4.10);
  • I) Cell wall synthesis inhibitors
    • inhibitors of glucan synthesis: validamycin (I.1.1), polyoxin B (I.1.2);
    • melanin synthesis inhibitors: pyroquilon (I.2.1), tricyclazole (I.2.2), carpropamid (I.2.3), dicyclomet (I.2.4), fenoxanil (I.2.5);
  • J) Plant defence inducers
    • acibenzolar-S-methyl (J.1.1), probenazole (J.1.2), isotianil (J.1.3), tiadinil (J.1.4), prohexadione-calcium (J.1.5); phosphonates: fosetyl (J.1.6), fosetyl-aluminum (J.1.7), phosphorous acid and its salts (J.1.8), calcium phosphonate (J.1.11), potassium phosphonate (J.1.12), potassium or sodium bicarbonate (J.1.9), 4-cyclopropyl-N-(2,4-dimethoxyphenyl)thiadiazole-5-carboxamide (J.1.10);
  • K) Unknown mode of action
    • bronopol (K.1.1), chinomethionat (K.1.2), cyflufenamid (K.1.3), cymoxanil (K.1.4), dazomet (K.1.5), debacarb (K.1.6), diclocymet (K.1.7), diclomezine (K.1.8), difenzoquat (K.1.9), difenzoquat-methylsulfate (K.1.10), diphenylamin (K.1.11), fenitropan (K.1.12), fenpyrazamine (K.1.13), flumetover (K.1.14), flumetylsulforim (K.1.60), flusulfamide (K.1.15), flutianil (K.1.16), harpin (K.1.17), methasulfocarb (K.1.18), nitrapyrin (K.1.19), nitrothal-isopropyl (K.1.20), tolprocarb (K.1.21), oxin-copper (K.1.22), proquinazid (K.1.23), seboctylamine (K.1.61), tebufloquin (K.1.24), tecloftalam (K.1.25), triazoxide (K.1.26), N′-(4-(4-chloro-3-trifluoromethyl-phenoxy)-2,5-dimethyl-phenyl)-N-ethyl-N-methyl formamidine (K.1.27), N′-(4-(4-fluoro-3-trifluoromethyl-phenoxy)-2,5-dimethyl-phenyl)-N-ethyl-N-methyl formamidine (K.1.28), N—[4-[[3-[(4-chlorophenyl)methyl]-1,2,4-thiadiazol-5-yl]oxy]-2,5-dimethyl-phenyl]—N—ethyl-N-methyl-formamidine (K.1.29), N′-(5-bromo-6-indan-2-yloxy-2-methyl-3-pyridyl)-N-ethyl-N-methyl-formamidine (K.1.30), N′—[5-bromo-6-[1-(3,5-difluorophenyl)-ethoxy]-2-methyl-3-pyridyl]—N—ethyl-N-methyl-formamidine (K.1.31), N′—[5-bromo-6-(4-isopropylcyclohexoxy)-2-methyl-3-pyridyl]—N—ethyl-N-methyl-formamidine (K.1.32), N′—[5-bromo-2-methyl-6-(1-phenylethoxy)-3-pyridyl]—N—ethyl-N-methyl-formamidine (K.1.33), N-(2-methyl-5-trifluoromethyl-4-(3-trimethylsilanyl-propoxy)-phenyl)-N-ethyl-N-methyl formamidine (K.1.34), N-(5-difluoromethyl-2-methyl-4-(3-trimethylsilanyl-propoxy)-phenyl)-N-ethyl-N-methyl formamidine (K.1.35), 2-(4-chloro-phenyl)—N—[4-(3,4-dimethoxy-phenyl)-isoxazol-5-yl]-2-prop-2-ynyloxy-acetamide (K.1.36), 3-[5-(4-chloro-phenyl)-2,3-dimethyl-isoxazolidin-3-yl]-pyridine (pyrisoxazole) (K.1.37), 3-[5-(4-methylphenyl)-2,3-dimethyl-isoxazolidin-3-yl]-pyridine (K.1.38), 5-chloro-1-(4,6-dimethoxy-pyrimidin-2-yl)-2-methyl-1H-benzoimidazole (K.1.39), ethyl (Z)-3-amino-2-cyano-3-phenyl-prop-2-enoate (K.1.40), picarbutrazox (K.1.41), pentyl N—[6-[[(Z)-[(1-methyltetrazol-5-yl)-phenyl-methylene]amino]oxymethyl]-2-pyridyl]carbamate (K.1.42), but-3-ynyl N—[6-[[(Z)-[(1-methyltetrazol-5-yl)-phenyl-methylene]amino]oxymethyl]-2-pyridyl]carbamate (K.1.43), ipflufenoquin (K.1.44), quinofumelin (K.1.47), benzothiazolinone (K.1.48), bromothalonil (K.1.49), 2-(6-benzyl-2-pyridyl)quinazoline (K.1.50), 2-[6-(3-fluoro-4-methoxy-phenyl)-5-methyl-2-pyridyl]quinazoline (K.1.51), dichlobentiazox (K.1.52), N′-(2,5-dimethyl-4-phenoxy-phenyl)-N-ethyl-N-methyl-formamidine (K.1.53), aminopyrifen (K.1.54), fluopimomide (K.1.55), N′—[5-bromo-2-methyl-6-(1-methyl-2-propoxy-ethoxy)-3-pyridyl]—N—ethyl-N-methyl-formamidine (K.1.56), N′—[4-(4,5-dichlorothiazol-2-yl)oxy-2,5-dimethyl-phenyl]—N—ethyl-N-methyl-formamidine (K.1.57), flufenoxadiazam (K.1.58), N-methyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzenecarbothioamide (K.1.59), N-methoxy—N—[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide (WO2018/177894, WO 2020/212513);


In the binary mixtures the weight ratio of the component 1) and the component 2) generally depends from the properties of the components used, usually it is in the range of from 1:10,000 to 10,000:1, often from 1:100 to 100:1, regularly from 1:50 to 50:1, preferably from 1:20 to 20:1, more preferably from 1:10 to 10:1, even more preferably from 1:4 to 4:1 and in particular from 1:2 to 2:1. According to further embodiments, the weight ratio of the component 1) and the component 2) usually is in the range of from 1000:1 to 1:1, often from 100: 1 to 1:1, regularly from 50:1 to 1:1, preferably from 20:1 to 1:1, more preferably from 10:1 to 1:1, even more preferably from 4:1 to 1:1 and in particular from 2:1 to 1:1. According to further embodiments, the weight ratio of the component 1) and the component 2) usually is in the range of from 20,000:1 to 1:10, often from 10,000:1 to 1:1, regularly from 5,000:1 to 5:1, preferably from 5,000:1 to 10:1, more preferably from 2,000:1 to 30:1, even more preferably from 2,000:1 to 100:1 and in particular from 1,000:1 to 100:1. According to further embodiments, the weight ratio of the component 1) and the component 2) usually is in the range of from 1:1 to 1:1000, often from 1:1 to 1:100, regularly from 1:1 to 1:50, preferably from 1:1 to 1:20, more preferably from 1:1 to 1:10, even more preferably from 1:1 to 1:4 and in particular from 1:1 to 1:2. According to further embodiments, the weight ratio of the component 1) and the component 2) usually is in the range of from 10:1 to 1:20,000, often from 1:1 to 1:10,000, regularly from 1:5 to 1:5,000, preferably from 1:10 to 1:5,000, more preferably from 1:30 to 1:2,000, even more preferably from 1:100 to 1:2,000 to and in particular from 1:100 to 1:1,000.


In the ternary mixtures, i.e. compositions comprising the component 1) and component 2) and a compound III (component 3), the weight ratio of component 1) and component 2) depends from the properties of the active substances used, usually it is in the range of from 1:100 to 100:1, regularly from 1:50 to 50:1, preferably from 1:20 to 20:1, more preferably from 1:10 to 10:1 and in particular from 1:4 to 4:1, and the weight ratio of component 1) and component 3) usually it is in the range of from 1:100 to 100:1, regularly from 1:50 to 50:1, preferably from 1:20 to 20:1, more preferably from 1:10 to 10:1 and in particular from 1:4 to 4:1. Any further active components are, if desired, added in a ratio of from 20:1 to 1:20 to the component 1). These ratios are also suitable for mixtures applied by seed treatment.


Preference is given to mixtures comprising as component 2) at least one active substance selected from inhibitors of complex III at Qo site in group A), more preferably selected from compounds (A.1.1), (A.1.4), (A.1.8), (A.1.9), (A.1.10), (A.1.12), (A.1.13), (A.1.14), (A.1.17), (A.1.21), (A.1.25), (A.1.34) and (A.1.35); particularly selected from (A.1.1), (A.1.4), (A.1.8), (A.1.9), (A.1.13), (A.1.14), (A.1.17), (A.1.25), (A.1.34) and (A.1.35).


Preference is also given to mixtures comprising as component 2) at least one active substance selected from inhibitors of complex III at Qi site in group A), more preferably selected from compounds (A.2.1), (A.2.3), (A.2.4) and (A.2.6); particularly selected from (A.2.3), (A.2.4) and (A.2.6).


Preference is also given to mixtures comprising as component 2) at least one active substance selected from inhibitors of complex II in group A), more preferably selected from compounds (A.3.2), (A.3.3), (A.3.4), (A.3.7), (A.3.9), (A.3.11), (A.3.12), (A.3.15), (A.3.16), (A.3.17), (A.3.18), (A.3.19), (A.3.20), (A.3.21), (A.3.22), (A.3.23), (A.3.24), (A.3.28), (A.3.31), (A.3.32), (A.3.33), (A.3.34), (A.3.35), (A.3.36), (A.3.37), (A.3.38) and (A.3.39); particularly selected from (A.3.2), (A.3.3), (A.3.4), (A.3.7), (A.3.9), (A.3.12), (A.3.15), (A.3.17), (A.3.19), (A.3.22), (A.3.23), (A.3.24), (A.3.31), (A.3.32), (A.3.33), (A.3.34), (A.3.35), (A.3.36), (A.3.37), (A.3.38) and (A.3.39).


Preference is also given to mixtures comprising as component 2) at least one active substance selected from other respiration inhibitors in group A), more preferably selected from compounds (A.4.5) and (A.4.11); in particular (A.4.11).


Preference is also given to mixtures comprising as component 2) at least one active substance selected from C14 demethylase inhibitors in group B), more preferably selected from compounds (B.1.4), (B.1.5), (B.1.8), (B.1.10), (B.1.11), (B.1.12), (B.1.13), (B.1.17), (B.1.18), (B.1.21), (B.1.22), (B.1.23), (B.1.25), (B.1.26), (B.1.29), (B.1.33), (B.1.34), (B.1.37), (B.1.38), (B.1.43), (B.1.46), (B.1.53), (B.1.54) and (B.1.55); particularly selected from (B.1.5), (B.1.8), (B.1.10), (B.1.17), (B.1.22), (B.1.23), (B.1.25), (B.1.33), (B.1.34), (B.1.37), (B.1.38), (B.1.43) and (B.1.46).


Preference is also given to mixtures comprising as component 2) at least one active substance selected from Delta14-reductase inhibitors in group B), more preferably selected from compounds (B.2.4), (B.2.5), (B.2.6) and (B.2.8); in particular (B.2.4).


Preference is also given to mixtures comprising as component 2) at least one active substance selected from phenylamides and acyl amino acid fungicides in group C), more preferably selected from compounds (C.1.1), (C.1.2), (C.1.4) and (C.1.5); particularly selected from (C.1.1) and (C.1.4).


Preference is also given to mixtures comprising as component 2) at least one active substance selected from other nucleic acid synthesis inhibitors in group C), more preferably selected from compounds (C.2.6), (C.2.7) and (C.2.8).


Preference is also given to mixtures comprising as component 2) at least one active substance selected from group D), more preferably selected from compounds (D.1.1), (D.1.2), (D.1.5), (D.2.4) and (D.2.6); particularly selected from (D.1.2), (D.1.5) and (D.2.6).


Preference is also given to mixtures comprising as component 2) at least one active substance selected from group E), more preferably selected from compounds (E.1.1), (E.1.3), (E.2.2) and (E.2.3); in particular (E.1.3).


Preference is also given to mixtures comprising as component 2) at least one active substance selected from group F), more preferably selected from compounds (F.1.2), (F.1.4) and (F.1.5).


Preference is also given to mixtures comprising as component 2) at least one active substance selected from group G), more preferably selected from compounds (G.3.1), (G.3.3), (G.3.6), (G.5.1), (G.5.3), (G.5.4), (G.5.5), G.5.6), G.5.7), (G.5.8), (G.5.9), (G.5.10) and (G.5.11); particularly selected from (G.3.1), (G.5.1) and (G.5.3).


Preference is also given to mixtures comprising as component 2) at least one active substance selected from group H), more preferably selected from compounds (H.2.2), (H.2.3), (H.2.5), (H.2.7), (H.2.8), (H.3.2), (H.3.4), (H.3.5), (H.4.9) and (H.4.10); particularly selected from (H.2.2), (H.2.5), (H.3.2), (H.4.9) and (H.4.10).


Preference is also given to mixtures comprising as component 2) at least one active substance selected from group I), more preferably selected from compounds (I.2.2) and (I.2.5).


Preference is also given to mixtures comprising as component 2) at least one active substance selected from group J), more preferably selected from compounds (J.1.2), (J.1.5), (J.1.8), (J.1.11) and (J.1.12); in particular (J.1.5).


Preference is also given to mixtures comprising as component 2) at least one active substance selected from group K), more preferably selected from compounds (K.1.41), (K.1.42), (K.1.44), (K.1.47), (K.1.57), (K.1.58) and (K.1.59); particularly selected from (K.1.41), (K.1.44), (K.1.47), (K.1.57), (K.1.58) and (K.1.59).







The compositions comprising mixtures of active ingredients can be prepared by usual means, e. g. by the means given for the compositions of compounds I.


EXAMPLES
Synthetic Process
Example 1: Methyl (2E)-2-[2-[[(E)-3-(2-Fluorophenyl)Ethylideneamino]Oxymethyl]-3-MethylPhenyl]-2-Methoxyimino-Acetate



embedded image


Step 1: 1-(2-Fluorophenyl)Ethanone Oxime

1-fluorophenyl)ethenone (10 g, 1.0 eq) was taken in methanol (300 ml) and hydroxyl amine hydrochloride (7.54 g, 1.8 eq) was added. Pyridine (33.45 g, 2 eq) was added drop wise at 25° C. Reaction mixture was stirred at 50° C. for 2 hr. Reaction was monitored using LCMS & TLC. Methanol was evaporated under vacuum. Crude mass was diluted with water (200 ml) and it was extracted with ethyl acetate (3 x 100 ml). Combined organic layer was again washed with water and brine. Organic layer was dried over sodium sulphate and concentrated under vacuum. Crude compound was purified by flash column chromatography. Pure compound was eluted with 0% to 20% ethyl acetate (EtOAc) in heptane. Evaporation of solvent afforded 8 g title compound as white solid (Yield 72%). 1H NMR 300 MHz, DMSO-d6: δ 11.4 (s ,1 H), 7.46-7.41 (m, 2 H), 7.27-7.23 (m, 2H), 2.14 (s, 3H).


Step 2: Ethyl (2E)-2-[2-[[(E)-1-(2-Fluorophenyl)Ethylideneamino]Oxymethyl]-3-Methyl-Phenyl]-2-Methoxyimino-Acetate (Ex. 2)

1-fluorophenyl)ethanone oxime (0.3 g, 3 eq) was taken in dimethyl formamide (DMF, 5 ml) and Cs2CO3 (3.27 g, 2.0 eq) was added. The reaction mixture was stirred for 30 minutes at room temperature (RT; at about 25° C.) and then added methyl (2E)-2-[2-(bromomethyl)-3-methyl-phenyl]-2-methoxyimino-acetate (0.6 g, 3.02 eq). The reaction mixture was stirred at RT for 32 hr and monitored by TLC and LCMS. Reaction was quenched with water (45 ml) and the product was extracted in ethyl acetate (3 x 35 ml). The combined organic layer was washed with brine (50 ml), dried over sodium sulphate and concentrated under vacuum. Crude material was purified by flash chromatography. Pure compound was eluted by using 35-20% EtOAc in heptane. Evaporation of solvent afforded an off-white solid title compound (0.328 g, 45% yield). 1H NMR (300 MHz, DMSO-d6): δ 7.56 - 7.36 (m, 2H), 7.33 - 7.32 (m, 4H), 7.03 (dd, J = 6.2, 2.8 Hz, 3H), 5.00 (s, 2H), 3.93 (s, 3H), 3.64 (s, 3H), 2.42 (s, 3H), 2.08 (d, J = 2.5 Hz, 3H).


Example 2: (2E)-2-[2-[[(E)-1-(2-Fluorophenyl)ethylideneamino]Oxymethyl]-3-Methyl-Phenyl]-2-Methoxyimino-N-Methyl-Acetamide



embedded image


Methyl (2E)-2-[2-[[(E)-1-(2-fluorophenyl)ethylideneamino]oxymethyl]-3-methyl-phenyl]-2-methoxyimino-acetate (ex. 1; 8 g,1 eq) was taken in THF (80 ml) and methylamine (40% aqueous) solution (16 ml, 2 vol) was added. The reaction mixture was stirred at 25° C. for 5 hr and monitored by TLC and LCMS. Reaction was quenched with water (200 ml) and the product was extracted in ethyl acetate (3 x 150 ml). The combined organic layer was washed with brine (150 ml), dried over sodium sulphate and concentrated under vacuum. Crude material was purified by flash chromatography. Pure compound was eluted by using 30-40% EtOAc in heptane. Evaporation of solvent afforded white solid title compound (7 g, 87.7% yield). 1H NMR (500 MHz, DMSO-d6): δ 8.20 (q, J = 4.7 Hz, 1H), 7.44 (ddt, J = 7.8, 5.6, 2.0 Hz, 2H), 7.37 -7.14 (m, 4H), 6.95 (dd, J = 7.1, 2.0 Hz, 1H), 5.01 (s, 2H), 3.86 (s, 3H), 2.65 (d, J = 4.8 Hz, 3H), 2.42 (s, 3H), 2.09 (d, J = 2.6 Hz, 3H).


Example 3: Methyl (2E)-2-[2-[[(E)-1-(3,5-Dichlorophenyl)Ethylideneamino]Oxymethyl]-3-MethylPhenyl]-2-Methoxyimino-Acetate



embedded image


Step 1: 1-(3,5-Dichlorophenyl)Ethanone Oxime

3-(3,5-Dichlorophenyl)ethanone (3.0 g, 3eq) was taken in methanol (30 ml) and NH2OH (0.735 g, 2 eq) followed by pyridine (3.04 g, 2.5 eq) were added. Reaction mixture was heated to 70° C. and stirred for 3 hr. Reaction was monitored using LCMS & TLC. Solvent was evaporated and the residue was diluted with water (50 ml). The product was extracted in with ethyl acetate (3 x 30 ml). The combined organic layer was washed with brine (50 ml), dried over sodium sulphate and concentrated under vacuum. Crude material was purified by flash chromatography. Pure compound was eluted by using 15-20% EtOAc in heptane. Evaporation of solvent afforded white solid compound 1-(3,5-dichlorophenyl)ethanone oxime (1 g, 92.6% yield).


Step 2: Methyl (2E)-2-[2-[[(E)-1-(3,5-Dichlorophenyl)Ethylideneamino]Oxymethyl]-3-MethylPhenyl]-2-Methoxyimino-Acetate

3-(3,5-Dichlorophenyl)ethanone oxime (0.4 g, 1 eq) was taken in acetonitrile (10 ml) and Cs2CO3 (1.8 g, 2.5 eq) was added. The reaction mixture was stirred for 30 min at RT and then added methyl (2E)-2-[2-(bromomethyl)-3-methyl-phenyl]-2-methoxyimino-acetate (0.65 g, 1.05 eq). The reaction mixture was stirred at RT for 3 hr and monitored by TLC and LCMS. Reaction was quenched with water (50 ml) and the product was extracted in ethyl acetate (3 x 30 ml). The combined organic layer was washed with brine (50 ml), dried over sodium sulphate and concentrated under vacuum. Crude material was purified by flash chromatography. Pure compound was eluted by using 20-25% EtOAc in heptane. Evaporation of solvent afforded an off-white solid title compound (0.6 g, 68% yield). 1H NMR (500 MHz, DMSO-d6): δ 7.66 (t, J = 1.9 Hz, 1H), 7.61 (d, J = 1.9 Hz, 2H), 7.36 - 7.23 (m, 2H), 7.05 - 6.98 (m, 1H), 5.04 (s, 2H), 3.91 (s, 3H), 3.70 (s, 3H), 2.43 (s, 3H), 2.30 (s, 3H).


Example 4: (2E)-2-[2-[[(E)-1-(3,5-Dichlorophenyl)Ethylideneamino]Oxymethyl]-3-Methyl-Phenyl]-2-Methoxyimino-N-Methyl-Acetamide



embedded image


Methyl (2E)-2-[2-[[(E)-3-(3,5-dichlorophenyl)ethylideneamino]oxymethyl]-3-methyl-phenyl]-2-methoxyimino-acetate (ex. 3; 0.6 g, 1 eq) was taken in THF (6 ml) and methyl amine (40% aq.) solution (1.2 ml, 2v) was added. The reaction mixture was stirred at RT for 3 hr and monitored by TLC and LCMS. Reaction was quenched with water (25 ml) and the product was extracted in ethyl acetate (3 x 20 ml). The combined organic layer was washed with brine (25 ml), dried over sodium sulphate and concentrated under vacuum. Crude material was purified by flash chromatography. Pure compound was eluted by using 40-45% EtOAc in heptane. Evaporation of solvent afforded white solid title compound (example 2, 0.53 g, 85% yield). 1H NMR (500 MHz, DMSO-d6): δ 8.24 (d, J = 4.8 Hz, 1H), 7.69 - 7.58 (m, 3H), 7.37 - 7.15 (m, 2H), 6.95 (dd, J = 7.1, 1.9 Hz, 1H), 5.05 (s, 2H), 3.86 (s, 3H), 2.68 (d, J = 4.7 Hz, 3H), 2.42 (s, 3H), 2.11 (s, 3H).


Example 5: Methyl (2E)-2-Methoxyimino-2-[3-Methyl-2-[[(E)-1-(P-Tolyl)Ethylideneamino] Oxymethyl]Phenyl]Acetate



embedded image


Step 1: 1-(P-Tolyl)ethanone Oxime

To a solution of 1-(p-tolyl)ethanone (1.0 g, 4.45 mmol, 3 eq.) in methanol (10 mL) was added hydroxylamine hydrochloride (0.77 g, 11.17 mmol, 1.5 eq) followed by addition of sodium acetate (1.82 g, 15 mmol, 2 eq.) at RT under nitrogen atmosphere. Reaction mixture was refluxed for 2 hrs. Reaction was monitored by TLC. Reaction mixture was concentrated on rotavapor. To this crude residue was added water (20 mL) and stirred for 0.5 hr. Solid material filtered and dried to obtain pure title compound (1.1 g, yield 98 %) as white solid. MS: [M + H] + 150.


Step 2: Methyl (2E)-2-Methoxyimino-2-[3-Methyl-1-[[(E)-3-(P-Tolyl)Ethylideneamino] Oxymethyl]Phenyl]Acetate

To a stirred solution of 1-(p-tolyl)ethanone oxime (0.15 g, 1.0 mmol, 1 eq) in acetonitrile (2 mL) was added Cs2CO3 (0.66 g, 2.0 mmol, 2 eq). The reaction mixture was stirred at 25° C. for 30 min. Then, methyl (2E)-2-[2-(bromomethyl)-3-methyl-phenyl]-2-methoxyimino-acetate (0.33 g, 1.1 mmol, 1.1 eq) was added. The mixture was stirred at 25° C. for 6 h. Reaction was monitored by TLC and LCMS. To this reaction mixture was added water (30 mL) and extracted with EtOAc (3 x 30 mL). Combined organic layer was washed with H2O (2 x 25 mL), followed by brine wash (2 x 20 mL). Organic layer was dried over Na2SO4 and Concentrated to afford crude compound which was further purified by flash column chromatography using 0-20% EtOAc in heptane as the eluent to obtain pure title compound as white solid (0.37 g, Yield 96%). 1H NMR (500 MHz, chloroform-d): δ 7.42 (d, J = 8.2 Hz, 2H), 7.26 - 7.19 (m, 3H), 7.07 (d, J = 8.0 Hz, 2H), 6.94 (dd, J= 7.2, 1.8 Hz, 2H), 5.03 (s, 2H), 3.94 (s, 3H), 3.70 (s, 3H), 2.41 (s, 3H), 2.27 (s, 3H), 2.06 (s, 3H). MS: [M + H] + 369.


Example 6: (2E)-2-Methoxyimino-N-Methyl-2-[3-Methyl-2-[[(E)-1-(P-Tolyl)Ethylidene-Amino]Oxymethyl]Phenyl]Acetamide



embedded image


To a stirred solution of methyl (2E)-2-methoxyimino-2-[3-methyl-1-[[(E)-3-(p-tolyl)-ethylideneamino]oxymethyl]phenyl]acetate in THF (5 mL), methyl amine solution in water (5.0 mL, 40 %) was added at RT. Reaction was continued for 1 hr. Reaction was monitored by TLC. Reaction mixture was evaporated on rotavapor, residue was diluted with EtOAc (20 mL) and washed with 1N HCl (3 x 20 mL), followed by brine wash (2 x 20 mL). Organic layer was dried over Na2SO4 and Concentrated to afford crude compound which was further purified by flash column chromatography using 0-50% EtOAc in heptane as the eluent to afford pure title compound as white solid (0.200 g, Yield 88%). 1H NMR (500 MHz, DMSO-d6): δ 8.20 (d, J = 5.0 Hz, 1H), 7.54 - 7.48 (m, 2H), 7.31 - 7.22 (m, 2H), 7.19 (d, J = 8.0 Hz, 2H), 6.95 (dd, J = 6.9, 2.1 Hz, 1H), 4.99 (s, 2H), 3.86 (s, 3H), 2.69 (d, J = 4.7 Hz, 3H), 2.43 (s, 3H), 2.31 (s, 3H), 2.08 (s, 3H). MS: [M + H]+ 368.


Example 7: (2E)-2-Methoxyimino-N-Methyl-2-[3-Methyl-2-[[(E)-[3,3,3-Trifluoro-1-[3-(TriFluoromethyl)Phenyl]Propylidene]Amino]Oxymethyl]Phenyl]Acetamide



embedded image


3,3,3-Trifluoro-1-[3-(trifluoromethyl)phenyl]propan-1-one (0.5 g, 1 eq), prepared in analogy to prior art process (Chem Commun, 2016, 52, 13668-13670), was taken in THF (10 ml) and (2E)-2-[2-(aminooxymethyl)-3-methyl-phenyl]-2-methoxyimino-N-methyl-acetamide (0.98 g, 2 eq) followed by Ti(OEt)4 (1.33 g, 3 eq) were added. The mixture was heated to 70° C. and stirred for 12 hr. The reaction was monitored by TLC and LCMS. The reaction was quenched with water (25 ml) followed by EtOAc (25 ml). The emulsion formed was filtered through celite and washed with EtOAc (50 ml). The layers were separated and the aequous layer was extracted in EtOAc (2 x 25ml). The combined organic layer was washed with brine (25 ml), dried over sodium sulphate and concentrated under vacuum. Crude material was purified by flash chromatography. Pure compound was eluted by using 40-45% EtOAc in heptane. Evaporation of solvent followed by crystallization in heptane afforded an off-white solid (0.34 g, 35% yield). 1H NMR (500 MHz, DMSO-d6): δ 8.27 (q, J = 4.7 Hz, 1H), 8.07 - 8.00 (m, 2H), 7.85 - 7.79 (m, 1H), 7.68 (t, J = 7.8 Hz, 1H), 7.35 - 7.24 (m, 2H), 6.97 (dd, J = 7.3, 1.7 Hz, 1H), 5.12 (s, 2H), 4.03-3.96 (q, J = 10 Hz, 2H), 3.86 (s, 3H), 2.67 (d, J = 4.7 Hz, 3H), 2.43 (s, 3H).


The following examples in Table S were synthesized as per general Scheme 1 described above (except Ex. 7 and 212 which were synthesized as per scheme 2) and characterized by LCMS as described in Table L.





TABLE L





LCMS Methods


LCMS Method A



Method details
Device details




Column: Agilent Eclipse Plus C18 (50 mm × 4.6 mm × 3 µm particles) Mobile Phase: A: 10 mM Ammonium formate in water. B: 0.1 % Formic acid in acetonitrile Gradient: 10 % B to 100 % B in 1.5 min. Hold 1 min 100 % B. 1 min 10 % B. Run time: 3.50 or 3.75 min. Flow: 1.2 ml/min; Column oven: 30° C./40° C.
LCMS2020 (Shimadzu) Ionization source: ESI Mass range: 100 - 800 amu Polarity: Dual (positive and negative simultaneous scan) Mode: Scan LC System: Nexera High pressure gradient system, Binary pump Detector: PDA Scanning wavelength: 220 nm / max plot








LCMS Method B



Method details
Device details




Column: Luna-C18 (30 mm × 2.0 mm × 3 µm particles) Mobile Phase: A: 0.037% Trifluoroacetic acid in water. B: 0.018% Trifluoroacetic acid in HPLC grade acetonitrile Gradient: 5-95% B in 3.00 min .5% B in 0.01 min, 5-95% B (0.01-1.60 min), 95-100% B (1.60 - 2.50 min), 100 -5% (2.50 - 2.52 min) with a hold at 5% B for 0.48 min. Flow: 0.8 mL/min; Column oven: 40° C.
LCMS DELIVER-220 (Shimadzu) Ionization source: ESI Mass range: 100 - 1000 amu Polarity: Positive Mode: Scan LC System: Nexera High pressure gradient system, Binary pump Detector: DAD Scanning wavelength: 220 nm / max plot








LCMS Method C



Method details
Device details




Column: Xbridge Shield RP18 (50 mm x 2.1 mm, 5 µm particles) Mobile Phase: A: H2O+10 mM NH4HCO3 B: Acetonitrile Gradient: 5% B in 0.40 min and 5-95% B at 0.40-3.40 min, hold on 95% B for 0.45 min, and then 95-5%B in 0.01 min. Flow: 0.8 ml/min; Column oven: 40° C.
Agilent Ionization source: ESI Mass range: 100 - 1000 amu Polarity: Positive Mode: Scan LC System: Nexera High pressure gradient system, Binary pump Detector: DAD Scanning wavelength: 220 nm / max plot


Column: Agilent Eclipse Plus C18 (50 mm × 4.6 mm × 3 µm particles) Mobile Phase: A: 10 mM NH4(HCOO) in water B: Acetonitrile Gradient: 10 % B to 100 % B in 5 min, hold on 100 % B for 3 min, 2 min 10 % B. Run time: 10 min. Flow: 1.2 ml/min; Column oven: 40° C.
LCMS 2020 (Shimadzu) Ionization source: ESI Mass range: 100 - 800 amu Polarity: Dual (positive and negative simultaneous scan) Mode: Scan LC System: Nexera High pressure gradient system, Binary pump Detector: PDA Scanning wavelength: 220 nm / max plot


Used LCMS Method in Table S to be found in Column LCMS.









TABLE S








No.
Structure
Rt [min]
Mass
LCMS




1


embedded image


2.08
373.7
A


2


embedded image


1.941
372
A


3


embedded image


2.252
422.9
A


4


embedded image


2.15
421.9
A


5


embedded image


2.144
369
A


6


embedded image


2.027
368
A


7


embedded image


2.123
490
A


8


embedded image


2.15
422.5
A


9


embedded image


2.19
423.5
A


10


embedded image


2.22
449.2 3
A


11


embedded image


2.13
448.4
A


12


embedded image


1.95
404
A


13


embedded image


2.18
435.3
A


14


embedded image


2.11
434.4
A


15


embedded image


2.05
425.2
A


16


embedded image


2.17
426.2
A


17


embedded image


1.99
447.1
A


18


embedded image


2.09
448.2
A


19


embedded image


2.06
404
A


20


embedded image


2.155
425
A


21


embedded image


2.06
408.5
A


22


embedded image


2.08
424
A


23


embedded image


2.04
458.3
A


24


embedded image


2.07
458.9
A


25


embedded image


2.07
441.05
A


26


embedded image


1.984
440
A


27


embedded image


1.97
408
A


28


embedded image


2.17
439
A


29


embedded image


2.09
438
A


30


embedded image


2.058
355
A


31


embedded image


1.963
354
A


32


embedded image


2.17
490
A


33


embedded image


2.25
456.9
A


34


embedded image


2.25
491
A


35


embedded image


2.1
446.8
A


36


embedded image


2.101
423
A


37


embedded image


2.155
422.9
A


38


embedded image


1.999
422
A


39


embedded image


2.059
422
A


40


embedded image


2.271
423.7
A


41


embedded image


2.15
422
A


42


embedded image


1.94
435.9
A


43


embedded image


2.09
436
A


44


embedded image


1.99
445.9
A


45


embedded image


2.13
397
A


46


embedded image


2.01
447
A


47


embedded image


2.08
440
A


48


embedded image


2.11
448
A


49


embedded image


2.18
441
A


50


embedded image


2.11
440.8
A


51


embedded image


2.2
441
A


52


embedded image


2.274
447.8
A


53


embedded image


2.094
379.8
A


54


embedded image


1.984
378
A


55


embedded image


2.02
396
A


56


embedded image


2.197
435.6
A


57


embedded image


2.208
446.1
A


58


embedded image


2.091
432.8
A


59


embedded image


2.26
457
A


60


embedded image


2.15
456
A


61


embedded image


2.22
437
A


62


embedded image


2.146
436
A


63


embedded image


2.099
436
A


64


embedded image


1.97
435
A


65


embedded image


2.24
437
A


66


embedded image


2.24
491
A


67


embedded image


2.15
490
A


68


embedded image


2.14
436
A


69


embedded image


2.059
440
A


70


embedded image


2.197
480
A


71


embedded image


2.091
479
A


72


embedded image


1.337
391
A


73


embedded image


1.256
390
A


74


embedded image


2.208
463
A


75


embedded image


2.101
462
A


76


embedded image


2.22
369
A


77


embedded image


2.1
368
A


78


embedded image


2.133
385
A


79


embedded image


2.005
384
A


80


embedded image


2.13
421
A


81


embedded image


2.037
420
A


82


embedded image


2.08
425
A


83


embedded image


1.92
424
A


84


embedded image


2.08
390
A


85


embedded image


2.03
372
A


86


embedded image


2.17
373
A


87


embedded image


2.08
391
A


88


embedded image


2.24
448
A


89


embedded image


2.15
449
A


90


embedded image


2.261
459
A


91


embedded image


2.155
458
A


92


embedded image


2.21
451
A


93


embedded image


2.11
450
A


94


embedded image


2.187
383
A


95


embedded image


2.22
397
A


96


embedded image


2.283
411
A


97


embedded image


2.208
431
A


98


embedded image


5.01
430
D


99


embedded image


2.08
382
A


100


embedded image


2.187
410
A


101


embedded image


2.22
403
A


102


embedded image


2.21
403
A


103


embedded image


2.08
373
A


104


embedded image


1.995
380
A


105


embedded image


2.144
396
A


106


embedded image


2.112
402
A


107


embedded image


2.123
402
A


108


embedded image


1.952
372
A


109


embedded image


2.123
402
A


110


embedded image


2.25
441
A


111


embedded image


2.2
431
A


112


embedded image


1.87
379
A


113


embedded image


2.11
430
A


114


embedded image


2.17
435
A


115


embedded image


2.113
369
A


116


embedded image


2.101
389
A


117


embedded image


2.197
423
A


118


embedded image


2.091
391
A


119


embedded image


2.12
434
A


120


embedded image


2.005
433
A


121


embedded image


2.2
431
A


122


embedded image


2.05
379
A


123


embedded image


2.04
385
A


124


embedded image


2.11
430
A


125


embedded image


1.93
378
A


126


embedded image


1.931
384
A


127


embedded image


1.984
368
A


128


embedded image


1.984
388
A


129


embedded image


2.112
391
A


130


embedded image


2.08
422
A


131


embedded image


1.984
390
A


132


embedded image


1.984
390
A


133


embedded image


2.187
439
A


134


embedded image


2.155
453
A


135


embedded image


2.29
513
A


136


embedded image


2.08
438
A


137


embedded image


2.18
383
A


138


embedded image


2.261
453
A


139


embedded image


2.155
382
A


140


embedded image


2.144
450
A


141


embedded image


2.069
452
A


142


embedded image


2.208
512
A


143


embedded image


2.197
447
A


144


embedded image


2.304
499
A


145


embedded image


2.261
463
A


146


embedded image


2.261
451
A


147


embedded image


2.24
449
A


148


embedded image


2.187
446
A


149


embedded image


2.347
498
A


150


embedded image


2.272
462
A


151


embedded image


2.261
450
A


152


embedded image


2.229
448
A


153


embedded image


2.155
389
A


154


embedded image


2.144
389
A


155


embedded image


1.995
380
A


156


embedded image


2.133
459
A


157


embedded image


2.132
388
A


158


embedded image


2.133
388
A


159


embedded image


1.941
379
A


160


embedded image


2.08
425
A


161


embedded image







162


embedded image


2.091
458
A


163


embedded image


2.229
403
A


164


embedded image


1.995
384
A


165


embedded image


2.187
382
A


166


embedded image


2.048
397
A


167


embedded image


2.219
440
A


168


embedded image


2.133
434
A


169


embedded image


2.112
409
A


170


embedded image


1.984
408
A


171


embedded image


2.29
423
A


172


embedded image


2.165
379
A


173


embedded image


2.069
422
A


174


embedded image


2.24
383
A


175


embedded image


2.261
383
A


176


embedded image


2.145
382
A


177


embedded image


2.165
391
A


178


embedded image


2.037
390
A


179


embedded image


1.888
396
A


180


embedded image


2.273
459
A


181


embedded image


2.261
426
A


182


embedded image


2.144
425
A


183


embedded image


2.251
383
A


184


embedded image


2.123
438
A


185


embedded image


2.23
462
A


186


embedded image


2.112
452
A


187


embedded image


2.027
426
A


188


embedded image


2.24
437
A


189


embedded image


2.144
436
A


190


embedded image


2.187
456
A


191


embedded image


2.229
453
A


192


embedded image


2.24
439
A


193


embedded image


2.101
402
A


194


embedded image


2.421
465
A


195


embedded image


2.144
382
A


196


embedded image


1.931
378
A


197


embedded image


2.176
458
A


198


embedded image


2.204
441
A


199


embedded image


2.144
440
A


200


embedded image


2.315
457
A


201


embedded image


2.133
439
A


202


embedded image


2.016
438
A


203


embedded image


2.283
383
A


204


embedded image


2.315
437
A


205


embedded image


2.15
490
A


206


embedded image


2.336
451
A


207


embedded image


2.229
450
A


208


embedded image


2.219
452
A


209


embedded image


2.187
450
A


210


embedded image


2.219
381
A


211


embedded image


2.091
380
A


212


embedded image


1.952
425
A


213


embedded image


2.123
391
A


214


embedded image


1.947
391
A


215


embedded image


2.357
463
A


216


embedded image


2.048
385
A


217


embedded image


2.208
395
A


218


embedded image


2.261
397
A


219


embedded image


2.101
394
A


220


embedded image


2.155
396
A


221


embedded image


2.251
410
A


222


embedded image


2.165
437
A


223


embedded image


2.048
436
A


224


embedded image


1.963
380
A


225


embedded image


1.853
379
A


226


embedded image


2.069
455
A


227


embedded image


2.187
456
A


228


embedded image


2.25
456
A


229


embedded image


2.24
437
A


230


embedded image


2.155
436.3
A


231


embedded image


2.16
422
A


232


embedded image


2.165
421
A


233


embedded image


2.21
469
A


234


embedded image


2.251
462
A


235


embedded image


2.251
465
A


236


embedded image


2.24
439
A


237


embedded image


2.325
463
A


238


embedded image


2.165
469
A


239


embedded image


2.315
437
A


240


embedded image


2.315
469
A


241


embedded image


2.208
468
A


242


embedded image


2.219
415
A


243


embedded image


2.112
414
A


244


embedded image


2.18
422
A


245


embedded image


2.176
456
A


246


embedded image


2.4
441
A


247


embedded image


2.283
440
A


248


embedded image


2.048
452
A


249


embedded image


2.133
441
A


250


embedded image


2.251
491
A


251


embedded image


2.197
457
A


252


embedded image


1.963
420
A


253


embedded image


208
421
A


254


embedded image


2.176
453
A


255


embedded image


2.229
490
A


256


embedded image


2.155
407
A


257


embedded image


2.251
503
A


258


embedded image


2.155
502
A


259


embedded image


2.251
453
A


260


embedded image


2.059
440
A


261


embedded image


2.165
452
A


262


embedded image


2.034
406
A


263


embedded image


2.144
441
A


264


embedded image


2.144
513
A


265


embedded image


2.229
514
A


266


embedded image


2.069
391
A


267


embedded image


390
2.005
A


268


embedded image


2.283
473
A


269


embedded image


2.229
457
A


270


embedded image


2.144
456
A


271


embedded image


2.176
472
A


272


embedded image


2.123
490
A


273


embedded image


2.123
436
A


274


embedded image


2.219
491
A


275


embedded image


2.165
491
A


276


embedded image


2.219
437
A


277


embedded image


1.952
398
A


278


embedded image


2.155
382
A


279


embedded image


2.347
411
A


280


embedded image


2.06
399
A


281


embedded image


2.176
431
A


282


embedded image


1.99
445.9
A


283


embedded image


2.12
407
A


284


embedded image


2.0
406
A


285


embedded image


2.16
387
A


286


embedded image


2.02
396
A


287


embedded image


2.14
397
A


288


embedded image


2.02
430
A


289


embedded image


2.20
457
A


290


embedded image


2.1
456
A


291


embedded image


1.95
394
A


292


embedded image


2.25
395
A


293


embedded image


2.02
386
A


294


embedded image


2.05
369
A


295


embedded image


1.94
384
A


296


embedded image


2.18
408
A


297


embedded image


2.20
395
A


298


embedded image


1.98
404
A


299


embedded image


2.14
394
A


300


embedded image


2.22
469
A


301


embedded image


2.1
468
A


302


embedded image


2.16
419
A


303


embedded image


2.04
418
A


304


embedded image


1.416
456.8
A


305


embedded image


1.95
447
B


306


embedded image


1.96
465
B


307


embedded image


1.99
427
B


308


embedded image


1.64
412
B


309


embedded image


1.9
413
B


310


embedded image


1.9
426
B


311


embedded image


1.74
413
B


312


embedded image


1.76
398
B


313


embedded image


1.88
411
B


314


embedded image


1.69
414
B


315


embedded image


1.82
412
B


316


embedded image


464
1.86
B


317


embedded image


1.86
399
B


318


embedded image


1.83
412
B


319


embedded image


1.93
413
B


320


embedded image


1.86
453
B


321


embedded image


1.87
446
B


322


embedded image


1.8
415
B


323


embedded image


1.386
456.7
A


324


embedded image


1.79
452
B


325


embedded image


1.64
456
B


326


embedded image


1.77
440
B


327


embedded image


1.83
436
B


328


embedded image


1.88
453
B


329


embedded image


1.78
410
B


330


embedded image


1.86
441
B


331


embedded image


1.77
452
B


332


embedded image


1.93
437
B


333


embedded image


2.25
503
A


334


embedded image


1.9
457
B


335


embedded image


1.53
549
A


336


embedded image


1.458
548.1
A


337


embedded image


1.67
468
B


338


embedded image


2
473
B


339


embedded image


1.85
426
B


340


embedded image


1.7
452
B


341


embedded image


1.65
437
B


342


embedded image


1.88
505
B


343


embedded image


1.95
506
B


344


embedded image


1.68
474
B


345


embedded image


1.6
440
B


346


embedded image


1.82
474
B


347


embedded image


1.92
355
B


348


embedded image


1.97
453
B


349


embedded image


3.04
522
C


350


embedded image


1.99
507
B


351


embedded image


1.92
457
B


352


embedded image


1.84
488
B


353


embedded image


1.86
419
B


354


embedded image


1.82
456
B


355


embedded image


2.97
535
C


356


embedded image


3.13
536
C


357


embedded image


1.62
458
B


358


embedded image


2.93
519
C


359


embedded image


1.95
459
B


360


embedded image


1.73
459
B


361


embedded image


1.76
475
B


362


embedded image


1.93
455
B


363


embedded image


1.89
506
B


364


embedded image


1.74
438
A


365


embedded image


1.7
441
B


366


embedded image


1.9
475
B


367


embedded image


1.84
354
B


368


embedded image


3.09
520
C


369


embedded image


1.87
458
B


370


embedded image


1.94
489
B


371


embedded image


3.79
523
C


372


embedded image


1.76
418
B


373


embedded image







374


embedded image


1.94
427
B


375


embedded image


1.91
472
B


376


embedded image


2.07
403
A


377


embedded image


1.95
402
A


378


embedded image


1.67
456
B


379


embedded image


2.2
457
A


380


embedded image


2.04
422
A


381


embedded image


2.13
423
A


382


embedded image


2.2
417
A


383


embedded image


2.07
416
A


384


embedded image


1.67
472
B


385


embedded image


1.78
473
B


386


embedded image


2.24
383
A


387


embedded image


2.25
383
A


388


embedded image


2.14
382
A


389


embedded image


2.11
382
A


390


embedded image


2.18
440
A


391


embedded image


2.15
437
A


392


embedded image


2.16
437
A


393


embedded image


2.03
436
A


394


embedded image


2.08
454
A


395


embedded image


2.19
421
A


396


embedded image


2.05
420
A


397


embedded image


2.23
381
A


398


embedded image


2.18
367
A


399


embedded image


2.03
380
A


400


embedded image


1.99
366
A


401


embedded image


2.03
396
A


402


embedded image


2.197
455
A


403


embedded image


1.25
436
A


404


embedded image


2.167
473
A


405


embedded image


2.22
472
A


406


embedded image


2.12
472
A


407


embedded image


2.26
512
A


408


embedded image


2.29
513
A


409


embedded image


2.21
459
A


410


embedded image


2.04
458
A


411


embedded image


2.24
489
A


412


embedded image


2.13
488
A


413


embedded image


2.25
498
A


414


embedded image


2.34
499
A


415


embedded image


2.18
509
A


416


embedded image


2.27
529
A


417


embedded image


2.24
494
A


418


embedded image


2.28
510
A


419


embedded image


2.106
528
A


420


embedded image


2.02
493
A


421


embedded image


2.18
457
A


422


embedded image


2.12
456
A


423


embedded image


2.03
448
A


424


embedded image


1.898
447
A


425


embedded image


2.26
517
A


426


embedded image


2.15
516
A


427


embedded image


1.86
507
B


428


embedded image


1.75
506
B


429


embedded image


2.27
491
A


430


embedded image


2.3
490
A


431


embedded image


2.17
490
A


432


embedded image


2.33
516
A


433


embedded image


2.4
514
A


434


embedded image


2.33
515
A


435


embedded image


2.15
514
A


436


embedded image


1.86
506
B


437


embedded image


1.71
436
B


438


embedded image


1.77
491
B


439


embedded image


1.82
507
B


440


embedded image


1.66
490
B


441


embedded image


1.71
506
B


442


embedded image


1.77
490
B


443


embedded image


1.72
489
B


444


embedded image


1.83
506
B


445


embedded image


2.23
500
A


446


embedded image


2.12
436
A


447


embedded image


1.87
475
B


448


embedded image


1.75
488
B


449


embedded image


1.8
490
B


450


embedded image


1.89
474
B


451


embedded image


1.78
474
B


452


embedded image


1.91
490
B


453


embedded image


1.85
488
B


454


embedded image


1.83
489
B


455


embedded image


1.9
491
B


456


embedded image


1.81
488
B


457


embedded image


1.72
488
B


458


embedded image


2.04
408
A


459


embedded image


2.16
409
A


460


embedded image


2.64
465
A


461


embedded image


2.00
438
A


462


embedded image


2.21
438
A


463


embedded image


2.31
472
A


464


embedded image


2.10
452
A






Biological Studies
Green House and Detached Leaf Tests

The compound was dissolved in a mixture of acetone and/or dimethylsulfoxide and the wetting agent/emulsifier Wettol, which is based on ethoxylated alkylphenoles, in a ratio (volume) solvent-emulsifier of 99 to 1 to give a total volume of 5 ml. Subsequently, water was added to total volume of 100 ml. This stock solution was then diluted with the described solvent-emulsifier-water mixture to the final concentration given in the table below.


Use Example 1. Curative Control of Soybean Rust on Soybeans Caused by Phakopsora Pachyrhizi (PHAKPA K4)

Leaves of potted soybean seedlings were inoculated with spores of Phakopsora pachyrhizi. The strain used contains the amino acid substitution F129L in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitors. To ensure the success of the artificial inoculation, the plants were transferred to a humid chamber with a relative humidity of about 95% and 20 to 24° C. for 24 hr. The next day the plants were cultivated for 3 days in a greenhouse chamber at 23 to 27° C. and a relative humidity between 60 and 80 %. Then the plants were sprayed to run-off with the previously described spray solution, containing the concentration of active ingredient or their mixture as described below. The plants were allowed to air-dry. Then the trial plants were cultivated for up to 14 days in a greenhouse chamber at 23 to 27° C. and a relative humidity between 60 and 80 %. The extent of fungal attack on the leaves was visually assessed as % diseased leaf area, the disease level of untreated controls was usually higher than 85 %.


Use Example 2. Protective Control of Soybean Rust on Soybeans Caused by Phakopsora Pachyrhizi (PHAKPA P2)

Leaves of potted soybean seedlings were sprayed to run-off with the previously described spray solution, containing the concentration of active ingredient or their mixture as described below. The plants were allowed to air-dry. The trial plants were cultivated for 2 days in a greenhouse chamber at 23-27° C. and a relative humidity between 60 and 80 %. Then the plants were inoculated with spores of Phakopsora pachyrhizi. The strain used contains the amino acid substitution F129L in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitors. To ensure the success the artificial inoculation, the plants were transferred to a humid chamber with a relative humidity of about 95 % and 20 to 24° C. for 24 hr. The trial plants were cultivated for up to 14 days in a greenhouse chamber at 23 to 27° C. and a relative humidity between 60 and 80 %. The extent of fungal attack on the leaves was visually assessed as % diseased leaf area, the disease level of untreated controls was usually higher than 85 %.


Use Example 3. Protective Control of Soybean Rust on Soybeans Caused by Phakopsora Pachyrhizi (PHAKPA P6)

Leaves of potted soybean seedlings were sprayed to run-off with the previously described spray solution, containing the concentration of active ingredient as described below. The plants were allowed to air-dry. The trial plants were cultivated for six days in a greenhouse chamber at 23-27° C. and a relative humidity between 60 and 80 %. Then the plants were inoculated with spores of Phakopsora pachyrhizi. The strain used contains the amino acid substitution F129L in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitors. To ensure the success the artificial inoculation, the plants were transferred to a humid chamber with a relative humidity of about 95 % and 23 to 27° C. for 24 hr. The trial plants were cultivated for up to 14 days in a greenhouse chamber at 23 to 27° C. and a relative humidity between 60 and 80 %. The extent of fungal attack on the leaves was visually assessed as % diseased leaf area, the disease level of untreated controls was usually higher than 85 %.


Use Example 4. Protective Control of Soybean Rust on Detached Soybean Leaves Caused by Phakopsora Pachyrhizi (PHAKPA P1 DL)

Leaves of potted soybean seedlings were sprayed to run-off with the previously described spray solution, containing the concentration of active ingredient as described below. The plants were left for drying in a green house chamber at 20° C. and 14 hours lightning over night. The next day, leaves were harvested and placed on water agar plates. Subsequently, the leaves were inoculated with spores of Phakopsora pachyrhizi. Two different isolates were used: one being sensitive to Qo inhibitors (wt); and one which contains the amino acid substitution F129L in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitors (F129L). Inoculated leaves were incubated for 16 to 24 h at room temperature in a dark dust chamber, followed by incubation for 2 to 3 weeks in an incubator at 20° C. and 12 hours light/day. The extent of fungal attack on the leaves was visually assessed as % diseased leaf area.


Micro Titer Plate Tests

The active compounds were formulated separately as a stock solution having a concentration of 10,000 ppm in dimethyl sulfoxide. The stock solutions were mixed according to the ratio, pipetted onto a micro titer plate (MTP) and diluted with water to the stated concentrations.


After addition of the respective spore suspension as indicated in the different use examples below, plates were placed in a water vapor-saturated chamber at a temperature of 18° C. Using an absorption photometer, the MTPs were measured at 405 nm 7 days after the inoculation. The measured parameters were compared to the growth of the active compound-free control variant (100%) and the fungus-free blank value to determine the relative growth in % of the pathogens in the respective active compounds.


Use Example 5. Activity Against Pyricularia Oryzae Causing Rice Blast (PYRIOR)

A spore suspension of Pyricularia oryzae in an aqueous biomalt or yeast-bactopeptone-glycerine or DOB solution was used.


Use Example 6. Activity Against Septoria Tritici Causing Leaf Blotch on Wheat (SEPTTR)

A spore suspension of Septoria tritici in an aqueous biomalt or yeast-bactopeptone-glycerine or DOB solution was used.


Use Example 7. Activity Against Colletotrichum Orbiculare Causing Anthracnose (COLLLA)

A spore suspension of Colletotrichum orbiculare in an aqueous 2% malt solution was used.


Use Example 8. Activity Against Leptosphaeria Nodorum Causing Wheat Leaf Spots (LEPTNO)

A spore suspension of Leptosphaeria nodorum in an aqueous biomalt or yeast-bactopeptone-glycerine or DOB solution was used.


Use Example 9. Activity Against Alternaria Solani Causing Early Blight (ALTESO, Wt and F129L)

Two different spore suspensions of Alternaria solani in an aqueous biomalt or yeast-bactopeptone-glycerine or DOB solution were used: a sensitive wild-type isolate (wt) and a Qo inhibitor-resistant isolate containing the amino acid substitution F129L in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitors (F129L).


Use Example 10. Activity Against Pyrenophora Teres Causing Net Blotch on Barley (PYRNTE, Wt and F129L)

Two different spore suspensions of Pyrenophora teres in an aqueous biomalt or yeast-bactopeptone-glycerine or DOB solution were used: a sensitive wild-type isolate (wt) and a Qo inhibitor-resistant isolate containing the amino acid substitution F129L in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitors (F129L).


Use Example 11. Activity Against Cercospora Sojina Causing Frogeye Leaf Spot of Soybeans (CERCSO)

A spore suspension of Cercospora sojina in an aqueous biomalt or yeast-bactopeptone-glycerine or DOB solution was then added.


Use Example 12. Activity Against Microdochium Nivale Causing Snow Mould (MONGNI)

A spore suspension of Microdochium nivale in an aqueous biomalt or yeast-bactopeptone-glycerine or DOB solution was used.


The results of the abovementioned use examples are given in the following Tables.


The test results in Tables 1 and C1 to C4 below are given for the control of phytopathogenic fungi containing the amino acid substitution F129L in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitors.





TABLE 1









Treatment with compound
% PHAKPA (F129L) Disease level


No.
Structure
P2 at 4 ppm
P2 at 16 ppm
P6 at 4 ppm
P6 at 16 ppm




1


embedded image


80
27
90
56


2


embedded image


5
0
26
1


3


embedded image


30
3
40
6


4


embedded image


2
0
13
1


5


embedded image


28
1
50
4


6


embedded image


1
0
19
1


8


embedded image


4
0
5
0


9


embedded image


35
23
41
4


10


embedded image


22
2
45
3


11


embedded image


23
1
20
0


12


embedded image


25
1
37
9


13


embedded image


28
0
25
0


14


embedded image


6
0
11
1


15


embedded image


4
0
24
1


17


embedded image


70
50
63
57


19


embedded image


87
0
87
1


20


embedded image


73
29
97
18


21


embedded image


100
77
97
88


22


embedded image


100
90
100
93


23


embedded image


12
1
20
1


24


embedded image


36
60
4
28


25


embedded image


16
3
50
2


26


embedded image


12
0
19
1


27


embedded image


5
0
32
0


28


embedded image



0

0


29


embedded image



0

0


30


embedded image


53
1
77
2


31


embedded image


0
0
4
0


32


embedded image


80
50
73
43


33


embedded image


50
33
60
75


34


embedded image


100
90
90
83


36


embedded image


100
42
100
43


37


embedded image


40
3
40
2


38


embedded image


37
4
47
1


39


embedded image


30
4
15
2


40


embedded image


40
18
63
22


41


embedded image


15
9
36
14


42


embedded image


60
23
60
20


43


embedded image


100
100
97
87


44


embedded image


77
17
77
21


46


embedded image


63
50
90
57


47


embedded image


13
0
12
0


48


embedded image


100
80
100
67


49


embedded image


60
18
60
7


50


embedded image


2
1
6
0


51


embedded image


28
2
15
0


52


embedded image


63
28
90
43


53


embedded image


63
17
100
47


54


embedded image


0
1
20
0


55


embedded image


3
1
13
5


56


embedded image


43
24
67
19


57


embedded image


25
8
43
15


58


embedded image


2
0
4
0


59


embedded image


67
20
63
11


60


embedded image


23
1
53
2


61


embedded image


70
15
90
18


62


embedded image


43
0
60
3


63


embedded image


90
77
93
77


64


embedded image


87
73
80
43


65


embedded image


93
77
100
87


66


embedded image


100
70
93
87


67


embedded image


67
2
80
30


69


embedded image


2
0
13
0


70


embedded image


30
0
10
1


71


embedded image


2
0
6
0


72


embedded image


100
87
93
80


73


embedded image


0

19



74


embedded image


27
6
16
3


75


embedded image


8
0
13
1


76


embedded image


30
3
9
0


77


embedded image


67
4
40
3


78


embedded image


40
1
30
1


79


embedded image


21
2
44
4


80


embedded image


50
10
30
3


81


embedded image


6
0
2
0


82


embedded image


87
57




83


embedded image


97
73




84


embedded image


0
0
0
0


85


embedded image


1
0
0
0


86


embedded image


12
3
23
3


87


embedded image


8
0
7
0


93


embedded image


83
32
43
37


94


embedded image


22
5
35
2


95


embedded image


11
0
33
4


96


embedded image


6
1
3
0


97


embedded image


4
1
1
0


98


embedded image


3
0
1
0


99


embedded image


43
12
87
33


100


embedded image


18
0
25
4


101


embedded image


70
37
60
17


102


embedded image


60
11
90
43


103


embedded image


40
3
35
4


104


embedded image


22
15
19
11


105


embedded image


18
1
39
13


106


embedded image


5
1
32
9


107


embedded image


1
0
15
1


108


embedded image


1
0
1
0


109


embedded image


8
1
12
0


110


embedded image


20
3
30
1


111


embedded image


28
8
46
10


112


embedded image


13
3
30
9


113


embedded image


25
26
41
25


114


embedded image


38
5
52
15


115


embedded image


83
63
92
75


116


embedded image


85
57
85
67


117


embedded image


85
10
88
12


118


embedded image


10
0
32
0


119


embedded image


93
63
92
63


120


embedded image


43
4
90
8


121


embedded image


100
98
98
92


122


embedded image


100
73
93
90


123


embedded image


100
82
90
78


124


embedded image


98
87
92
75


125


embedded image


72
9
90
44


126


embedded image


87
34
95
70


127


embedded image


90
44
93
62


128


embedded image


32
2
77
2


129


embedded image


28
1
24
2


130


embedded image


20
1
40
1


131


embedded image


0
0
2
0


132


embedded image


1
0
6
0


133


embedded image


1
0
2
0


134


embedded image


37
10
22
7


135


embedded image


15
1
16
2


136


embedded image


1
0
3
2


137


embedded image


19
2
50
5


138


embedded image


47
2
35
1


139


embedded image


47
2
72
24


140


embedded image


8
0
13
4


141


embedded image


2
0
2
0


142


embedded image


19
5
26
5


143


embedded image


4
0
15
0


144


embedded image


87
80
92
90


145


embedded image


28
8
37
16


146


embedded image


73
12
77
48


147


embedded image


73
18
95
18


148


embedded image


9
2
13
7


149


embedded image


83
45
87
31


150


embedded image


56
8
70
29


151


embedded image


37
3
53
6


152


embedded image


24
1
38
7


153


embedded image


12
3
22
1


154


embedded image


30
13
63
9


155


embedded image


97
30
93
20


156


embedded image


27
0
47
3


157


embedded image


1
0
1
0


158


embedded image


0
0
2
0


159


embedded image


28
2
28
1


160


embedded image


100
97
87
90


161


embedded image


100
100
100
90


162


embedded image


0
0
1
0


163


embedded image


20
1
47
9


164


embedded image


5
0
27
0


165


embedded image


0
0
17
0


166


embedded image


100
83
90
43


167


embedded image


2
0
9
0


168


embedded image


2
0
5
0


169


embedded image


77
0
77
0


170


embedded image


9
0
4
0


171


embedded image


100
100
80
50


172


embedded image


35
1
83
12


173


embedded image


100
53
97
17


174


embedded image


100
100
80
70


175


embedded image


100
97
100
93


176


embedded image


100
100
100
90


177


embedded image


100
21
87
47


178


embedded image


6
0
2
0


179


embedded image


100
47
90
28


180


embedded image


40
7
5
0


181


embedded image


22
11
33
5


182


embedded image


6
0
13
0


183


embedded image


16
0
38
2


184


embedded image


42
4
16
1


185


embedded image


100
67
90
77


186


embedded image


1
0
2
0


187


embedded image


100
100
90
90


188


embedded image


1
0
11
0


189


embedded image


82
28
97
37


190


embedded image


20
0
45
3


191


embedded image


77
2
83
22


193


embedded image


15
0
14
0


196


embedded image


1
0
11
5


197


embedded image


0
0
2
0


198


embedded image


4
1
0
0


199


embedded image


0
0
0
0


200


embedded image


93
73
100
77


202


embedded image


90
22
100
47


203


embedded image


87
32
93
32


204


embedded image


50
4
80
5


206


embedded image


100
67
100
90


207


embedded image


40
11
83
5


211


embedded image


100
43
100
77


213


embedded image


50
3
40
11


214


embedded image


14
0
28
4


215


embedded image


87
37
87
33


216


embedded image


77
13
80
29


217


embedded image


97
53
93
100


218


embedded image


100
87
100
100


219


embedded image


60
8
87
43


220


embedded image


90
30
100
77


221


embedded image


100
63
100
100


222


embedded image


100
57
100
93


223


embedded image


4
0
28
0


224


embedded image


97
100
100
100


225


embedded image


83
27
100
97


226


embedded image


28
3
57
7


227


embedded image


100
47
100
57


228


embedded image


5
0
22
2


229


embedded image


27
2
77
6


230


embedded image


22
1
73
4


231


embedded image


0
0
2
0


232


embedded image


100
73
100
83


233


embedded image


100
57
87
27


234


embedded image


53
18
53
15


235


embedded image


100
73
87
77


236


embedded image


97
77
97
100


238


embedded image


100
53
100
77


240


embedded image


70
8
73
3


241


embedded image


3
0
33
12


242


embedded image


87
10
87
20


243


embedded image


4
0
37
1


244


embedded image


14
0
15
2


245


embedded image


28
8
13
2


246


embedded image


40
15
77
7


247


embedded image


16
2
33
8


248


embedded image


33
2
30
2


249


embedded image


87
37
90
43


250


embedded image


90
90
90
80


251


embedded image


80
80
80
80


252


embedded image


50
3
87
32


253


embedded image


100
87
100
57


254


embedded image


100
77
100
100


255


embedded image


97
83
100
87


256


embedded image


50
18
70
20


257


embedded image


93
35
100
57


258


embedded image


32
7
73
8


259


embedded image


80
17
93
40


260


embedded image


22
0
22
0


261


embedded image


70
9
87
32


262


embedded image


63
1
47
4


263


embedded image


80
15
73
22


266


embedded image


67
18
90
43


267


embedded image


2
0
10
4


268


embedded image


63
6
60
17


269


embedded image


5
0
18
0


270


embedded image


3
0
0
1


271


embedded image


5
1




272


embedded image


60
8




273


embedded image


60
3




277


embedded image


100
60
100
100


278


embedded image


90
60
90
93


282


embedded image



15

18


283


embedded image


83
30
87
22


284


embedded image


63
44
62
34


285


embedded image


87
50
90
35


286


embedded image


67
15
97
27


288


embedded image


87
30
97
20


290


embedded image


92
14
83
21


294


embedded image


1
1
2
0


295


embedded image


2
0
11
0


296


embedded image


100
40
100
83


297


embedded image


90
37
87
37


298


embedded image


63
7
97
37


299


embedded image


53
13
53
22


302


embedded image


47
4
47
3


303


embedded image


2
0
12
0


304


embedded image


53
28
100
37


312


embedded image


100
53




314


embedded image


100
40




315


embedded image


100
60




321


embedded image


100
40




324


embedded image


2
1
12
0


325


embedded image


24
4
22
1


326


embedded image


25
0
30
1


327


embedded image


23
3
48
4


328


embedded image


33
8
23
5


329


embedded image


100
53
100
73


330


embedded image


83
24
93
17


335


embedded image


77
53
80
25


336


embedded image


63
20
50
17


337


embedded image


9
0
13
1


340


embedded image


23
4
42
7


344


embedded image


6
0
16
0


345


embedded image


22
1
32
1


346


embedded image


4
0
5
0


349


embedded image


97
50
97
35


354


embedded image


17
2
21
4


355


embedded image


34
7
48
4


357


embedded image


13
1
18
0


358


embedded image


77
17
83
18


359


embedded image


100
37
100
43


360


embedded image


53
9
80
5


361


embedded image


80
18
88
31


363


embedded image


29
1
25
2


365


embedded image


77
15
97
43


366


embedded image


53
13
83
12


367


embedded image


63
9
93
30


368


embedded image


83
47
90
73


372


embedded image


85
26
85
16


373


embedded image


77
27
100
38


375


embedded image


47
8
40
6


378


embedded image


18
1
17
1


380


embedded image


53
5
60
12


387


embedded image


60
30
80
47


388


embedded image


1
0
3
0


389


embedded image


28
4
43
3


390


embedded image


22
0
18
2


393


embedded image


93
55
93
42


394


embedded image


9
3
12
2


395


embedded image


43
4
67
18


396


embedded image


3
0
4
0


399


embedded image


67
8
90
15


400


embedded image


2
0
8
0


401


embedded image


17
5
32
4


405


embedded image


97
27
70
27


406


embedded image


97
30
67
23


407


embedded image


12
6
17
4


408


embedded image


30
12
33
13


409


embedded image


77
40
83
73


410


embedded image


9
0
35
1


412


embedded image


47
6
40
6


413


embedded image


40
15
33
15


414


embedded image


53
9
53
15


415


embedded image


47
5
67
11


416


embedded image


57
27
67
25


417


embedded image


35
18
63
22


418


embedded image


70
33
73
57


419


embedded image


40
18
60
12


420


embedded image


8
0
12
1


421


embedded image


100
33
87
57


422


embedded image


30
0
32
2


423


embedded image


100
57
93
53


424


embedded image


100
27
97
50


425


embedded image


27
28
53
40


426


embedded image


7
1
27
10


427


embedded image


100
90
60
47


428


embedded image


70
11
83
20


429


embedded image


83
50
67
43


430


embedded image


22
6
37
17


431


embedded image


32
7
40
12


432


embedded image


12
0
13
3


433


embedded image


83
67
80
57


435


embedded image


93
57
87
60


436


embedded image


70
15
73
27


437


embedded image


2
0
8
0


440


embedded image


93
23
73
23


441


embedded image


100
43
97
50


442


embedded image


100
93
80
77


444


embedded image


100
47
83
53


445


embedded image


15
1
30
2


446


embedded image


2
0
6
0


447


embedded image


7
0
33
1


449


embedded image


33
10
57
9


450


embedded image


3
1
4
1


451


embedded image


1
0
2
0


452


embedded image


60
6
70
14


458


embedded image


93
57
83
50


461


embedded image


26
2
52
6


462


embedded image


37
6
55
10


463


embedded image


6
0
3
0


464


embedded image


1
0
8
0






Comparative Trials




TABLE C1











PHAKPA (F129L) Disease level (%)


Compound
Structure
P2 at 4 ppm
P2 at 16 ppm
P6 at 4 ppm
P6 at 16 ppm




Trifloxystrobin as comparative example


embedded image


71
17
79
33


Ex. 9


embedded image


35
23
41
4









TABLE C2









PHAKPA (F129L) Disease level (%)


Compound
Structure
P2 at 4 ppm
P6 at 4 ppm




Comparative example


embedded image


6
30


Ex. 231


embedded image


0
2


Comparative example


embedded image


27
70


Ex. 58


embedded image


0
4


Comparative example


embedded image


100
100


Ex. 6


embedded image


0
23


Comparative example


embedded image


40
80


Ex. 158


embedded image


1
4


Comparative example


embedded image


43
80


Ex. 157


embedded image


0
2


Comparative example


embedded image


100
97


Ex. 4


embedded image


2
17


Comparative example


embedded image


87
100


Ex. 31


embedded image


0
12


Comparative example


embedded image


12
38


Ex. 8


embedded image


1
13


Comparative example


embedded image


43
77


Ex. 41


embedded image


4
35


Comparative example


embedded image


35
83


Ex. 165


embedded image


0
27


Comparative example


embedded image


87
97


Ex. 130


embedded image


33
67


Comparative example


embedded image


60
70


Ex. 188


embedded image


2
30


Comparative example


embedded image


43
90


Ex. 73


embedded image


1
37


Untreated

100
99









TABLE C3









PHAKPA (F129L) Disease level (%)


Compound
Structure
P2 at 16 ppm
P6 at 16 ppm




Comparative example


embedded image


23
28


Ex. 120


embedded image


6
15


Comparative example


embedded image


87
80


Ex. 126


embedded image


32
60


Comparative example


embedded image


37
28


Ex. 113


embedded image


17
6


Comparative example


embedded image


37
63


Ex. 159


embedded image


0
0


Comparative example


embedded image


11
4


Ex. 60


embedded image


0
0


Comparative example


embedded image


16
35


Ex. 12


embedded image


3
9


Comparative example


embedded image


15
15


Ex. 27


embedded image


0
0


Comparative example


embedded image


70
53


Ex. 282


embedded image


15
18


Comparative example


embedded image


23
32


Ex. 205


embedded image


1
1


Untreated

100
87









TABLE C4









PHAKPA (F129L) Disease level (%)


Compound
Structure
P2 at 16 ppm
P6 at 16 ppm




Comparative example


embedded image


27
17


Ex. 3


embedded image


2
1


Comparative example


embedded image


80
87


Ex. 56


embedded image


32
15


Comparative example


embedded image


87
90


Ex. 36


embedded image


47
57


Comparative example


embedded image


25
10


Ex. 5


embedded image


1
4


Comparative example


embedded image


67
33


Ex. 216


embedded image


20
15


Comparative example


embedded image


83
77


Ex. 1


embedded image


28
47


Comparative example


embedded image


43
13


Ex. 37


embedded image


0
0


Comparative example


embedded image


87
43


Ex. 30


embedded image


2
1


Comparative example


embedded image


57
60


Ex. 181


embedded image


12
5


Comparative example


embedded image


87
53


Ex. 155


embedded image


23
18


Comparative example


embedded image


100
90


Ex. 28


embedded image


30
18


Comparative example


embedded image


63
43


Ex. 154


embedded image


25
17


Comparative example


embedded image


93
83


Ex. 76


embedded image


1
0


Comparative example


embedded image


90
80


Ex. 86


embedded image


6
7


Comparative example


embedded image


73
70


Ex. 153


embedded image


5
1


Comparative example


embedded image


80
43


Ex. 104

37
28


Comparative example


embedded image


11
9


Ex. 244


embedded image


0
2


Comparative example


embedded image


1
22


Ex. 131


embedded image


0
0


Untreated

>90
>85






The results in Tables C1 to C4 show that the specific substituent at position R3 improves the fungicidal activity against phytopathogenic fungi containing the amino acid substitution F129L in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitors compared to compounds where the position R3 is unsubstituted.





TABLE C5










Fungal growth (%)


Concentration applied (ppm)
0.016
0.016
0.016
0.016


Compound
Structure
PYRIOR
ALTESO wt
ALTESO F129L
MONGNI




Comparative example from WO 2017/157923


embedded image


87
98
100
97


Ex. 158


embedded image


38
66
79
71









TABLE C6a















PHAKPA P1 DL Disease level (%) Qo I-sensitive wt isolate (0 % F129L)




Test concentration (ppm)


Compound
Structure
0
0.3
1
3
10
30
100
300




Comparative example from WO 17/157923


embedded image


93
78
80
77
48
30
18
5


Ex. 158


embedded image


38
7
2
1
4
5
4









TABLE C6b















PHAKPA P1 DL Disease level (%) Qo I-resistant F129L isolate (100 % F129L)




Test concentration (ppm)


Compound
Structure
0
0.3
1
3
10
30
100
300




Comparative example from WO 17/157923


embedded image


93
88
90
95
92
90
65
52


Ex. 158


embedded image


87
57
8
2
4
4
5






The results in Tables C5 to C6b show that the compounds to the present invention significantly improve the fungicidal activity against phytopathogenic fungi containing the amino acid substitution F129L in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitors compared to the use of a compound disclosed in WO 2017/157923.





TABLE C7a










Fungal growth (%)


Concentration applied (ppm)
0.016
0.016
0.025
4


Compound
Structure
PYRIOR
ALTESO wt
PYRNTE wt
CERCSO




Comparative example from WO 98/23156


embedded image


100
94
84
33


Ex. 9


embedded image


38
73
44
11









TABLE C7b








PHAKPA (F129L) Disease level (%)


Compound
Structure
P2 at 4 ppm




Comparative example from WO 98/23156


embedded image


17


Ex. 9


embedded image


6


Untreated

92









TABLE C8a










Fungal growth (%)


Concentration applied (ppm)
0.016
0.063
0.016
4


Compound
Structure
PYRIOR
COLLLA
ALTESO wt
ALTESO F129L




Comparative example from WO 98/23156


embedded image


100
77
94
87


Ex. 84


embedded image


48
33
43
39









TABLE C8b










Fungal growth (%)


Concentration applied (ppm)
0.25
0.25
0.063
0.016


Compound
Structure
PYRNTE wt
PYRNTE F129L
LEPTNO
MONGNI




Comparative example from WO 98/23156


embedded image


87
84
79
86


Ex. 84


embedded image


39
49
60
32






The results in Table C7a to C8b show that the specific substituent Ra of the terminal phenyl improves the fungicidal activity against phytopathogenic fungi compared to compounds from the prior art.





TABLE C9









Fungal growth (%)


Concentration applied (ppm)
0.016
0.063
4


Compound
Structure
PYRIOR
LEPTNO
CERCSO




Comparative example from WO 98/23156


embedded image


58
100
56


Ex. 9


embedded image


38
67
11









TABLE C10











Fungal growth (%)


Concentration applied (ppm)
0.016
0.063
0.016
4
0.016


Compound
Structure
PYRIOR
LEPTNO
ALTESO F129L
CERCSO
MONGNI




Comparative example from WO 98/23156


embedded image


49
93
85
66
84


Ex. 8


embedded image


13
70
55
27
54









TABLE C11a











Fungal growth (%)


Concentration applied (ppm)
0.016
0.25
0.063
0.016
0.016


Compound
Structure
PYRIOR
SEPTTR
LEPTNO
ALTESO wt
ALTESO F129L




Comparative example from WO 98/23156


embedded image


39
77
95
100
87


Ex. 8


embedded image


13
57
70
56
52









TABLE C11b








Fungal growth (%)


Concentration applied (ppm)
4
0.016


Compound
Structure
CERCSO
MONGNI




Comparative example from WO 98/23156


embedded image


60
80


Ex. 8


embedded image


27
54









TABLE C12











Fungal growth (%)


Concentration applied (ppm)
0.016
0.25
0.063
0.016
0.25


Compound
Structure
PYRIOR
SEPTTR
COLLLA
MONGNI
PYRTNE F129L




Comparative example from WO 98/23156


embedded image


87
61
81
69



Comparative example from WO 98/23156


embedded image


82
89
93
84
87


Ex. 76


embedded image


43
0
39
35
66









TABLE C13











Fungal growth (%)


Concentration applied (ppm)
0.063
0.016
0.016
0.25
4


Compound
Structure
LEPTNO
ALTESO wt
ALTESO F129L
PYRNTE wt
CERCSO




Comparative example from WO 98/23156


embedded image


85
67
66
59
71


Comparative example from WO 98/23156


embedded image


65
93
81
53
67


Comparative example from WO 98/23156


embedded image


100
100
87
78
87


Ex. 76


embedded image


39
55
37
39
28









TABLE C14











Fungal growth (%)


Concentration applied (ppm)
0.016
0.25
0.063
0.016
0.016


Compound
Structure
PYRIOR
SEPTTR
COLLLA
ALTESO wt
ALTESO F129L




Comparative example from WO 98/23156


embedded image


80
100
81
93
95


Comparative example from WO 98/23156


embedded image


81
87
93
89
93


Ex. 77


embedded image


20
49
39
73
69









TABLE C15a











Fungal growth (%)


Concentration applied (ppm)
0.016
0.25
0.063
0.016
0.016


Compound
Structure
PYRIOR
SEPTTR
COLLLA
ALTESO wt
ALTESO F129L




Comparative example from WO 98/23156


embedded image


88
39
82
94
100


Comparative example from WO 98/23156


embedded image


83
39
89
81
89


Ex. 153


embedded image


50
0
55
71
68









TABLE C15b










Fungal growth (%)


Concentration applied (ppm)
0.063
0.25
4
0.016


Compound
Structure
LEPTNO
PYRNTE wt
CERCSO
MONGNI




Comparative example from WO 98/23156


embedded image


88
57
62
95


Comparative example from WO 98/23156


embedded image



69
61



Ex. 153


embedded image


55
31
26
75









TABLE C16a











Fungal growth (%)


Concentration applied (ppm)
0.016
0.25
0.063
0.25
0.016


Compound
Structure
PYRIOR
SEPTTR
COLLLA
ALTESO wt
ALTESO F129L




Comparative example from WO 98/23156


embedded image


100
59
82
43
90


Ex. 157


embedded image


15
20
63
27
57









TABLE C16b










Fungal growth (%)


Concentration applied (ppm)
0.25
0.25
4
0.016


Compound
Structure
PYRNTE wt
PYRNTE F129L
CERCSO
MONGNI




Comparative example from WO 98/23156


embedded image


76
80
78
100


Ex. 157


embedded image


54
58
36
56









TABLE C17









PHAKPA (F129L) Disease level (%)


Compound
Structure
P2 at 4 ppm
P6 at 16 ppm




Comparative example from WO 98/23156


embedded image


83
57


Comparative example from WO 98/23156


embedded image


80
37


Comparative example from WO 98/23156


embedded image


60
30


Ex. 76


embedded image


35
4


Comparative example from WO 98/23156


embedded image



45


Comparative example from WO 98/23156


embedded image


67
67


Ex. 77


embedded image


37
20


Comparative example from WO 98/23156


embedded image



23


Ex. 9


embedded image



1


Comparative example from WO 98/23156


embedded image


20
9


Ex. 157


embedded image


1
1


Comparative example from WO 98/23156


embedded image


83
87


Comparative example from WO 98/23156


embedded image


47
18


Ex. 153


embedded image


19
5


Untreated

92
75









TABLE C18









PHAKPA (F129L) Disease level (%)


Compound
Structure
P2 at 1 ppm
P6 at 4 ppm




Comparative example from WO 98/23156


embedded image


32
43


Ex. 8


embedded image


6
1


Untreated

92
75






The result in Tables C9 to C18 show that the specific substituent R4 improves the fungicidal activity against phytopathogenic fungi compared to compounds from the prior art.

Claims
  • 1. (canceled)
  • 2. The method according to claim 7, wherein in formula I R1 is selected from O and NH; and R2 is selected from CH and N, provided that R2 is N in case R1 is NH.
  • 3. The method according to claim 7, wherein in formula I R3 is selected from C1-C2-alkyl, C1-C2-monohaloalkyl, C1-C2-dihaloalkyl, C3-C4-cycloalkyl and —O—C1-C2-alkyl.
  • 4. The method according to 3 claim 7, wherein in formula I R4 is selected from C1-C4-alkyl, —C(═O)—C1-C2-alkyl, C1-C4-haloalkyl and -(C1-C2-alkyl)-O-(C1-C2-alkyl).
  • 5. The method according to 4 claim 7, wherein in formula I Ra is selected from is selected from C1-C3-alkyl, C2-C3-alkenyl, C2-C3-alkynyl, —O—C1-C3-alkyl, —C(═N—O—C1-C2-alkyl)-C1-C2-alkyl, —O—CH2—C(═N—O—C1-C2-alkyl)-C1-C2-alkyl, C3-C4-cycloalkyl, -C1-C2-alkyl-C3-C4-cycloalkyl, —O—C3-C4-cycloalkyl, phenyl, 3- to 5-membered heterocycloalkyl and 5- or 6-membered heteroaryl, wherein said heterocycloalkyl and heteroaryl besides carbon atoms contain 1 or 2 heteroatoms selected from N, O and S, wherein said phenyl and heteroaryl are bound directly or via an oxygen atom or via a methylene linker, and wherein the aliphatic and cyclic moieties of Ra are unsubstituted or carry 1, 2 or 3 of identical or different groups Rb which independently of one another are selected from halogen, CN, methyl and C1-haloalkyl.
  • 6. The method according to claim 7, wherein the phytopathogenic fungi are soybean rust (Phakopsora pachyrhizi and/or P. meibomiae).
  • 7. A method for combating phytopathogenic fungi containing an amino acid substitution F129L in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitors, comprising: treating curatively and/or preventively the plants or the plant propagation material of said plants that are at risk of being diseased from the said phytopathogenic fungi, and/orapplying to the said phytopathogenic fungi with an effective amount of at least one compound of formula I wherein R1 is selected from O and NH;R2 is selected from CH and N;R3 is selected from halogen, C1-C4-alkyl, C2-C4-alkenyl, C1-C2-monohaloalkyl, C1-C2-dihaloalkyl, monohalo-ethenyl, dihalo-ethenyl, C3-C6-cycloalkyl and —O—C1-C4-alkyl;R4 is selected from C1-C4-alkyl, C2-C4-alkenyl, —C(═O)—C1-C2-alkyl, C1-C4-haloalkyl, C2-C4-haloalkenyl, -(C1-C2-alkyl)-O-(C1-C2-alkyl) and -CH2-cvclopropyl;Ra is selected from halogen, CN, —NR5R6, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, —O—C1-C4-alkyl, —C(═N—O—C1-C4-alkyl)-C1-C4-alkyl, —C(═O)—C1-C4-alkyl , —O—CH2—C(═N—O—C1-C4-alkyl)-C1-C4-alkyl, C3-C6-cycloalkyl, C3-C6-cycloalkenyl, -C1-C2-alkyl-C3-C6-cycloalkyl, —O—C3-C6-cycloalkyl, phenyl, 3- to 6-membered heterocycloalkyl, 3- to 6-membered heterocycloalkenyl and 5- or 6-membered heteroaryl, wherein said heterocycloalkyl, heterocycloalkenyl and heteroaryl besides carbon atoms contain 1, 2 or 3 heteroatoms selected from N, O and S, wherein said phenyl, heterocycloalkyl, heterocycloalkenyl and heteroaryl are bound directly or via an oxygen atom or via a C1-C2-alkylene linker, and wherein the aliphatic and cyclic moieties of Ra are unsubstituted or carry 1, 2, 3, 4 or up to the maximum number of identical or different groups Rb: Rb is selected from halogen, CN, NH2, NO2, C1-C4-alkyl, C1-C4-haloalkyl, —O—C1-C4-alkyl, and —O—C1-C4-haloalkyl;R5, R6 are independently of each other selected from the group consisting of H, C1-C6-alkyl, C1-C6-haloalkyl and C2-C4-alkynyl;n is an integer selected from 0, 1, 2, 3, 4 and 5;and in form of stereoisomers and tautomers thereof, and the N-oxides and the agriculturally acceptable salts thereof.
  • 8. A compound of formula I wherein R1 is selected from O and NH;R2 is selected from CH and N;R3 is selected from C1-C4-alkyl, C2-C4-alkenyl, C1-C2-monohaloalkyl, C1-C2-dihaloalkyl, monohalo-ethenyl, dihalo-ethenyl, C3-C6-cycloalkyl and —O—C1- C4-alkyl;R4 is selected from C1-C4-alkyl, C2-C4-alkenyl, C1-C4-haloalkyl, C2-C4-haloalkenyl, -(C1-C2-alkyl)-O-(C1-C2-alkyl) and -(C1-C2-alkyl)-O-(C1-C2-haloalkyl);Ra is selected from halogen, C1-C4-haloalkyl, C2-C4-haloalkenyl, C2-C4-haloalkynyl, C3-C6-cycloalkyl, C3-C6-cycloalkenyl, -C1-C2-alkyl-C3-C6-cycloalkyl, phenyl, 3- to 6-membered heterocycloalkyl, 3- to 6-membered heterocycloalkenyl and 5- or 6-membered heteroaryl, wherein said heterocycloalkyl, heterocycloalkenyl and heteroaryl besides carbon atoms contain 1, 2 or 3 heteroatoms selected from N, O and S, wherein said phenyl, heterocycloalkyl, heterocycloalkenyl and heteroaryl are bound directly or via an oxygen atom or via a C1-C2-alkylene linker, and wherein the cyclic moieties of Ra carry 1, 2 or 3 substituents selected from halogen and C1-C4-haloalkyl,and wherein the aliphatic and cyclic moieties of Ra further carry 0, 1, 2 or up to the maximum number of identical or different groups Rb—Rb is selected from CN, NH2, NO2, C1-C4-alkyl and —O—C1-C4-alkyl;n is an integer selected from 0, 1, 2, 3, 4 and 5;and in form of stereoisomers and tautomers thereof, and the N-oxides and the agriculturally acceptable salts thereof.
  • 9. The compound according to claim 8, wherein R1 is selected from O and NH; and R2 is selected from CH and N, provided that R2 is N in case R1 is NH.
  • 10. The compound according to claim 8, wherein R3 is selected from C1-C2-alkyl, C1-C2-monohaloalkyl, C1-C2-dihaloalkyl, C3-C4-cycloalkyl and —O—C1-C2-alkyl.
  • 11. The compound according to claim 8, wherein R4 is selected from C1-C4-alkyl, C1-C4-haloalkyl and -(C1-C2-alkyl)-O-(C1-C2-alkyl).
  • 12. The compound according to claim 8, wherein n is 1, 2 or 3.
  • 13. The compound according to claim 8, wherein Ra is selected from halogen, C1-C4-haloalkyl, C2-C4-haloalkenyl, C2-C4-haloalkynyl, C3-C4-cycloalkyl, —CH2—C3-C4-cycloalkyl, phenyl, 3- to 5-membered heterocycloalkyl and 5- or 6-membered heteroaryl, wherein said heterocycloalkyl and heteroaryl besides carbon atoms contain 1 or 2 heteroatoms selected from N, O and S, wherein said phenyl, heterocycloalkyl and heteroaryl are bound directly or via a methylene linker, and wherein the cyclic moieties of Ra carry 1, 2, or 3 substituents selected from halogen and C1-C2-haloalkyl, and wherein cyclic moieties of Ra further carry 0, 1, 2 or 3 identical or different groups Rb selected from CN, NH2, NO2, C1-C4-alkyl and —O—C1-C4-alkyl.
  • 14. An agrochemical composition comprising an auxiliary and at least one compound of formula I, as defined in claim 8 or in the form of a stereoisomer or an agriculturally acceptable salt or a tautomer or N-oxide thereof.
  • 15. A method for combating phytopathogenic fungi comprising: treating curatively and/or preventively the plants or the plant propagation material of said plants that are at risktex of being diseased from the said phytopathogenic fungi, and/or applying to the said phytopathogenic fungi, at least one compound of formula I as defined in claim 8 .
Priority Claims (3)
Number Date Country Kind
20171943.2 Apr 2020 EP regional
20210705.8 Nov 2020 EP regional
21165162.5 Mar 2021 EP regional
PCT Information
Filing Document Filing Date Country Kind
PCT/EP2021/059730 4/15/2021 WO